sidestream
dark
field
imag
sdf
technic
rel
simpl
method
visual
microcircul
howev
current
goldstandard
consensu
analysi
ca
sdf
film
take
approxim
hour
per
film
limit
applic
sdf
clinic
set
lead
increas
expens
due
analysi
low
qualiti
film
develop
subject
point
care
score
system
bedsid
evalu
microcircul
bem
could
provid
realtim
intervent
point
optim
care
critic
patient
object
studi
evalu
whether
bemscor
correctli
identifi
film
suffici
insuffici
diagnost
qualiti
defin
catwenti
variablelength
microcircul
film
taken
level
canin
tooth
select
databas
film
avail
ca
studi
three
observ
train
use
instruct
video
evalu
five
qualiti
paramet
stabil
content
illumin
focu
pressur
bem
perform
view
score
film
four
time
immedi
success
five
qualiti
paramet
score
perfect
suffici
insuffici
accord
ca
analysi
fourth
view
consid
analysi
bem
qualiti
analysi
consid
suffici
paramet
score
insuffici
repeat
reproduc
assess
assess
film
random
order
three
time
daili
three
daysbem
passfail
assess
match
ca
time
individu
observ
agreement
agreement
bem
ca
chang
studi
period
day
respect
indic
accur
qualiti
analysi
singl
bemscor
train
video
mean
cumul
bem
qualiti
score
sd
similar
ca
mean
sd
howev
mean
individu
bemparamet
score
differ
ca
reflect
differ
observ
interpretationhigh
level
interobserv
agreement
strong
correl
ca
passfail
assess
demonstr
bem
qualiti
evalu
produc
repeat
reliabl
result
variat
individu
paramet
score
may
reflect
systemat
erron
assign
certain
paramet
individu
bia
toward
assess
certain
featur
nevertheless
impact
overal
evalu
film
qualiti
studi
provid
platform
investig
whether
rapid
semiquantit
analysi
microcircul
similarli
feasibl
sidestream
dark
field
imag
sdf
straightforward
techniqu
evalu
microcircul
howev
current
consensu
analysi
ca
sdf
film
timeconsum
therebi
restrict
clinic
applic
sdf
subject
bedsid
score
system
bem
propos
could
rapidli
provid
semiquantit
assess
previous
shown
observ
could
accur
evalu
film
qualiti
paramet
object
present
studi
assess
correl
bem
ca
quantit
microcircul
paramet
three
observ
train
use
instruct
video
evalu
four
quantiti
paramet
total
vessel
densiti
tvd
capillari
vessel
densiti
cvd
perfus
vessel
densiti
pvd
microvascular
flow
index
mfi
fifteen
variablelength
microcircul
film
suffici
qualiti
taken
level
canin
tooth
select
databas
film
avail
consensu
analysi
paramet
score
lowest
highest
bem
perform
view
score
film
four
time
immedi
success
final
score
consid
analysi
bem
perform
film
random
order
three
time
daili
three
day
ca
score
divid
quintil
paramet
mean
bem
score
calcul
convers
bem
score
mean
ca
score
calcul
per
observ
per
dayth
mean
tvd
pvd
bem
score
quintil
lower
mean
bem
score
quintil
mean
bem
score
quintil
highest
mean
bem
score
pvd
mean
cvd
pvd
mfi
valu
bem
score
lower
mean
valu
bem
score
parallel
although
tvd
never
receiv
bem
score
mean
ca
valu
film
bem
score
lower
higher
bem
score
mean
tvd
mfi
valu
bem
score
higher
mean
valu
bem
score
similar
valu
obtain
individu
studi
daythi
studi
demonstr
rapid
semiquantit
assess
microcircul
use
bemscor
produc
repeat
reliabl
result
although
signific
overlap
exist
studi
requir
evalu
valu
techniqu
clinic
set
object
compar
two
noninvas
blood
pressur
nibp
measur
devic
petmap
doppler
invas
blood
pressur
ibp
measur
normotens
anesthetis
awaken
dog
design
prospect
clinic
studi
anim
ten
femal
dog
age
month
averag
month
weight
kg
averag
kg
undergo
routin
spay
intervent
blood
pressur
measur
procedur
induct
gener
anesthesia
cathet
place
dorsal
pedal
arteri
invas
systol
sap
diastol
dap
mean
map
arteri
blood
pressur
obtain
nibp
cuff
place
ipsilater
front
limb
five
consecut
measur
obtain
indirect
devic
consid
mean
measur
ibp
obtain
simultan
five
nibp
measur
also
consid
mean
measur
measur
awaken
dog
obtain
four
hour
surgeri
doppler
systol
sap
petmap
systol
sap
diastol
dap
mean
map
arteri
blood
pressur
evalu
compar
correspond
ibp
use
blandaltman
analysi
percentag
pair
measur
mean
differ
mmhg
also
evalu
sap
dap
sap
result
agreement
ibp
nibp
measur
obtain
petmap
doppler
assess
blandaltman
analysi
anesthetis
dog
indirect
devic
underestim
direct
blood
pressur
petmap
bia
standard
deviat
mmhg
mmhg
mmhg
mmhg
mmhg
mmhg
sap
dap
map
respect
doppler
bia
mmhg
mmhg
sap
awaken
dog
petmap
underestim
sap
overestim
dap
map
bia
mmhg
mmhg
mmhg
mmhg
mmhg
mmhg
sap
dap
map
respect
doppler
underestim
ibp
bia
mmhg
mmhg
anesthetis
awaken
patient
percentag
valu
lie
within
mmhg
ibp
higher
equal
petmap
compar
doppler
conclus
result
suggest
better
perform
petmap
devic
predict
ibp
normotensiveanesthetis
normotensiveawaken
dog
intracrani
hypertens
ich
associ
high
morbid
mortal
canin
veterinari
medicin
yet
remain
difficult
clinic
diagnos
lack
easili
feasibl
avail
diagnost
method
prevent
clinic
studi
preval
caus
treatment
ich
recent
transcrani
doppler
ultrasonographi
tcd
report
noninvas
diagnost
method
human
howev
preliminari
report
use
techniqu
dog
publish
studi
evalu
repeat
reproduc
tcd
basilar
left
right
cranial
cerebr
arteri
healthi
beagl
dogstcd
perform
use
standard
ultrasound
machin
level
basilar
arteri
left
right
cranial
cerebr
arteri
six
adult
beagl
dog
systol
diastol
averag
veloc
resist
ri
pulsatil
index
pi
assess
vessel
repeat
evalu
calcul
intraclass
correl
coeffici
icc
three
separ
consecut
measur
everi
dog
icc
also
determin
reproduc
measur
three
consecut
day
procedur
ecg
blood
pressur
clinic
paramet
monitoredstatist
analysi
show
highli
signific
repeat
measur
paramet
systol
diastol
averag
veloc
ri
pi
blood
vessel
n
icc
p
systol
veloc
ri
pi
also
significantli
reproduc
basilar
arteri
n
icc
p
left
right
cranial
cerebr
arteri
n
icc
p
howev
signific
correl
found
basilar
cerebr
blood
flow
velocitiesmeasur
pi
ri
basal
cranial
cerebr
arteri
use
tcd
appear
high
intraoper
repeat
reproduc
howev
measur
perform
basilar
arteri
higher
day
reproduc
sinc
technic
skill
requir
assess
paramet
subject
appear
less
complic
level
basilar
arteri
tcd
clinic
set
probabl
advoc
basal
arteryin
conclus
tcd
character
high
intraobserv
repeat
reproduc
make
techniqu
promis
tool
measur
pi
ri
report
correl
intracrani
pressur
intracrani
hypertens
ich
associ
high
morbid
mortal
canin
veterinari
medicin
yet
remain
difficult
clinic
diagnos
furthermor
mani
patient
suspect
suffer
ich
treat
sed
anticonvuls
besid
impact
molecul
patient
neurolog
examin
variabl
influenc
cardiovascular
system
studi
evalu
effect
variou
sed
anticonvuls
pulsatil
resist
index
pi
ri
measur
transcrani
doppler
ultrasonographi
tcd
healthi
beagl
dog
addit
evalu
effect
ivabradin
specif
neg
chronotrop
tcd
find
tcd
perform
level
basilar
arteri
six
adult
beagl
dog
techniqu
perform
prior
inject
molecul
administr
acepromazin
ace
lgkg
iv
diazepam
dia
mgkg
iv
medetomidin
med
lgkg
im
ivabradin
iva
mgkg
iv
washout
period
least
hour
respect
administr
drug
procedur
ecg
heart
rate
hr
blood
pressur
bp
monitor
result
analyz
use
repeat
measur
anova
correl
clinic
paramet
pi
ri
investig
use
pearson
correl
result
consid
signific
p
significantli
lower
pi
ri
valu
mean
pi
ci
mean
ri
ci
obtain
med
pi
dog
iva
significantli
increas
compar
dia
differ
significantli
groupshr
significantli
lower
med
compar
group
iva
compar
bp
significantli
lower
ace
iva
med
clinic
paramet
significantli
correl
pi
ri
dia
ace
significantli
influenc
ri
pi
howev
med
significantli
decreas
ri
pi
find
agre
previou
report
describ
decreas
icp
provok
med
pi
posit
correl
icp
effect
appear
independ
effect
med
hr
sinc
iva
also
significantli
decreas
hr
yet
significantli
affect
pi
ri
conclus
blood
pressur
heart
rate
significantli
affect
pi
ri
hypertroph
cardiomyopathi
hcm
commonli
diagnos
heart
diseas
cat
littl
document
effect
treatment
outcom
cat
preclin
diseas
therefor
prospect
cohort
studi
undertaken
evalu
effect
treatment
atenolol
outcom
cat
asymptomat
hcm
hypothes
mortal
would
increas
cat
hcm
compar
match
control
group
healthi
cat
administr
atenolol
would
reduc
cardiac
mortal
occult
felin
hcmcat
enrol
time
period
prospect
openlabel
observ
studi
diagnosi
hcm
base
transthorac
echocardiographi
cat
either
treat
atenolol
mgcat
po
receiv
treatment
decis
treat
base
owner
prefer
suggest
clinician
anim
complianc
regard
pill
administr
baselin
echocardiogram
analyz
morbid
mortal
monitor
month
thereaft
annual
recheck
phone
interview
refer
veterinarian
owner
time
period
group
compar
nonpair
ttest
introduct
systol
anterior
motion
mitral
valv
sam
dynam
left
ventricular
outflow
obstruct
frequent
observ
felin
hypertroph
cardiomyopathi
hcm
howev
sever
case
sam
also
observ
cat
without
left
ventricular
hypertrophi
lvh
find
could
interpret
earli
stage
diseas
yet
accompani
lvh
altern
could
specul
dynam
outflow
obstruct
could
caus
intraventricular
pressur
overload
suffici
enough
induc
lvh
later
stage
studi
conduct
test
hypothesi
sam
potenti
caus
myocardi
stress
myocardi
damag
measur
plasma
ntprobnp
serum
troponini
level
cat
sam
associ
lvh
method
studi
base
retrospect
analysi
cat
underw
cardiac
investig
heart
murmur
perform
board
cardiologist
cat
diagnos
sam
associ
lvh
ivsd
lvfwd
bmode
mmode
measur
via
colour
doppler
echocardiographi
plasma
ntprobnp
cardiopet
test
idexx
laboratori
inc
serum
high
sensit
troponini
hsctni
hs
idexx
laboratori
inc
measur
patient
well
serum
urea
creatinin
thyroxin
concentr
associ
biomark
ntprobnp
hsctni
concentr
echocardiograph
valu
myocardi
thick
left
atrial
dimens
aortic
peak
veloc
determin
use
spearman
correl
coeffici
rho
result
cat
euthyroid
show
evid
renal
diseas
mean
hsctni
measur
perform
one
cat
due
unsuit
sampl
eleven
cat
show
ntprobnp
valu
normal
refer
limit
pmoll
median
concentr
pmoll
rang
five
cat
show
hsctni
valu
normal
refer
limit
ngml
median
concentr
ngml
rang
signific
posit
correl
aortic
peak
veloc
ntprobnp
conclus
ntprobnp
increas
cat
sam
without
lvh
suggest
presenc
myocardi
stress
appear
proport
degre
outflow
obstruct
deriv
aortic
peak
veloc
cat
also
present
degre
myocardi
insult
suggest
increas
serum
hsctni
whether
increas
biomark
concentr
relat
saminduc
pressur
overload
earli
stage
primari
myocardi
diseas
need
evalu
appropri
longitudin
studi
heart
murmur
caus
turbul
blood
flow
vibrat
cardiac
structur
turbul
blood
flow
young
anim
may
origin
congenit
structur
heart
diseas
physiolog
phenomena
preval
heart
murmur
congenit
heart
diseas
gener
ie
non
referr
felin
popul
unknown
aim
prospect
studi
determin
preval
heart
murmur
young
cat
determin
preval
congenit
heart
diseas
young
cat
heart
murmursin
total
domest
shorthair
cat
age
month
underw
routin
physic
examin
prior
vaccin
may
st
march
st
cat
adopt
program
run
either
dierenasiel
breda
eo
dierenopvangcentrum
tilburg
cat
murmur
murmur
time
grade
point
maximum
intens
determin
subsequ
mmode
doppler
transthorac
echocardiographi
continu
ecg
monitor
performedheart
murmur
detect
anim
congenit
heart
diseas
detect
anim
acquir
heart
diseas
anim
identifi
heart
diseas
anim
murmursin
anim
without
heart
diseas
dynam
right
ventricular
outflow
tract
obstruct
caus
murmur
case
turbul
within
left
ventricl
caus
casesin
anim
acquir
heart
diseas
pulmonari
hypertens
associ
abstrusu
diagnosedin
cat
congenit
heart
diseas
isol
defect
found
cat
tricuspid
valv
dysplasia
cat
dynam
left
ventricular
outflow
tract
obstruct
associ
mitral
valv
dysplasia
cat
ventricular
septal
defect
cat
doubl
chamber
right
ventricl
cat
pulmon
stenosi
cat
combin
defect
found
cat
ventricular
septal
defect
tricuspid
valv
dysplasia
ventricular
septal
defect
doubl
chamber
right
ventricl
ventricular
septal
defect
atrial
septal
defect
cat
ventricular
septal
defect
pulmon
stenosi
cat
mitral
tricuspid
valv
dysplasia
catsin
conclus
prospect
studi
found
preval
heart
murmur
preval
congenit
heart
diseas
atrioventricular
valv
abnorm
ventricular
septal
defect
common
dynam
left
ventricular
outflow
tract
obstruct
dlvoto
common
caus
heart
murmur
adult
cat
obstruct
caus
systol
anterior
motion
sam
mitral
valv
sam
typic
observ
adult
cat
human
hypertroph
cardiomyopathi
hcm
mani
studi
support
concept
structur
deform
mitral
valv
papillari
muscl
could
primari
caus
sam
congenit
malform
mitral
valv
caus
sam
dlvoto
observ
dog
peopl
believ
exist
cat
yet
report
aim
studi
report
clinic
echocardiograph
find
young
cat
dlvotothirteen
domest
shorthair
kitten
week
age
present
systol
heart
murmur
may
st
march
st
cat
underw
physic
examin
preced
mmode
doppler
echocardiographi
kitten
adopt
program
run
either
dierenasiel
breda
eo
dierenopvangcentrum
tilburg
eo
nine
kitten
male
four
femal
kitten
asymptomat
dlvoto
caus
sam
present
anim
uninterruptedli
eleven
high
heart
rate
two
seven
cat
normal
left
ventricular
dimens
nlvd
six
cat
concentr
left
ventricular
hypertrophi
clvh
five
cat
papillari
muscl
abnorm
note
accessori
papillari
muscl
two
enlarg
papillari
muscl
three
two
clvhtwelv
anim
reexamin
month
initi
examin
anim
still
asymptomat
heart
murmur
dlvoto
could
longer
detect
nine
anim
five
initi
clvh
four
initi
nlvd
three
anim
heart
murmur
dlvoto
still
present
two
cat
nlvd
develop
clvh
one
cat
initi
clvh
continu
clvhtreatment
atenolol
instig
three
cat
continu
dlvoto
clvh
two
cat
reexamin
treatment
atenolol
led
complet
revers
clvh
case
intervent
radiolog
techniqu
use
palliat
malign
nonmalign
caus
vascular
obstruct
intrins
extrins
lesionsthre
dog
present
larg
nonresect
cardiac
mass
obstruct
venou
return
right
atrium
venou
return
heart
sever
obstruct
lead
congest
subsequ
ascit
head
swell
pleural
effus
due
extens
natur
diseas
intervent
palli
approach
pursu
transatri
selfexpand
metal
nitinol
stent
place
cdvc
crvc
order
restor
venou
return
heart
via
blood
flow
stent
intersticesin
case
stent
placement
success
resolut
clinic
sign
achiev
two
dog
requir
addit
stent
placement
month
month
respect
stent
occlus
case
restent
result
ascit
resolut
substanti
reduct
one
dog
euthan
month
follow
initi
stent
placement
gener
system
declin
return
moder
ascit
second
dog
remain
aliv
month
follow
initi
stent
placement
diuret
therapi
moder
ascit
present
third
die
undetermin
caus
month
laterto
author
knowledg
first
report
longterm
palli
transatri
stent
cardiac
tumor
affect
venou
return
heart
stent
well
toler
canin
patient
surgic
option
possibl
irish
wolfhound
iw
dog
high
preval
heart
diseas
particularli
dilat
cardiomyopathi
dcm
atrial
fibril
af
prospect
longitudin
studi
irish
wolfhound
investig
one
veterinari
cardiologist
dcm
diagnos
dog
case
dcm
accompani
af
af
without
evid
dcm
diagnos
dog
patholog
investig
heart
iw
collect
fix
buffer
formalin
base
recent
result
cardiovascular
examin
five
group
establish
normal
heart
group
dcm
sinusrhythm
group
dcm
af
group
dcm
af
congest
heart
failur
chf
group
af
left
ventricular
revers
remodel
lvrr
due
medic
therapi
diagnosi
dcm
group
heart
evalu
one
pathologist
blind
clinic
diagnosi
gross
inspect
includ
measur
weight
size
architectur
left
lv
right
rv
ventricl
three
site
lv
rv
interventricular
septum
iv
histolog
evalu
extend
myocardi
fibrosi
adipocyt
infiltr
angiosclerosi
grade
semiquantitativelyiw
dcm
chf
group
die
significantli
younger
year
dog
normal
heart
year
concern
gross
patholog
find
heart
clinic
dcm
diagnosi
lv
chamber
dilat
case
group
group
papillari
muscl
appear
grossli
promin
flatten
group
control
dog
lv
rv
myocardium
show
mild
interstiti
collagen
deposit
singl
adipocyt
normal
vessel
contrast
heterogen
find
seen
group
heart
show
mild
moder
multifoc
myocardi
fibrosi
moder
diffus
infiltr
adipocyt
within
lv
myocardium
mild
angiosclerosi
five
heart
histolog
normal
one
dog
attenu
wavi
fiber
seen
apic
region
lv
iv
normal
case
rv
show
mild
interstiti
fibrosi
mild
moder
adipocyt
case
groupsin
conclus
patholog
find
heart
iw
affect
dcm
differ
breed
furthermor
gross
histolog
find
variabl
correspond
clinic
diagnosi
case
irish
wolfhound
iw
dog
high
preval
heart
diseas
particularli
dilat
cardiomyopathi
dcm
atrial
fibril
af
prospect
longitudin
studi
irish
wolfhound
investig
one
veterinari
cardiologist
dcm
diagnos
dog
case
dcm
accompani
af
addit
af
without
evid
dcm
diagnos
dog
patholog
investig
heart
iw
collect
fix
buffer
formalin
base
recent
result
cardiovascular
examin
three
group
establish
dcm
af
group
af
without
evid
dcm
group
normal
heart
group
aim
studi
investig
histopatholog
find
left
right
atria
iw
atrial
fibril
compar
normal
heart
iw
heart
evalu
one
pathologist
blind
clinic
diagnosi
heart
inspect
grossli
two
cross
section
left
laa
right
raa
atrial
appendag
embed
paraffin
wax
stain
h
e
picrosiriu
red
myocardi
fibrosi
adipocyt
infiltr
atria
grade
semiquantitavelymean
age
sd
dog
time
death
yr
gross
histopatholog
find
left
atrial
appendag
laa
significantli
differ
among
group
dog
af
group
raa
dilat
ml
median
ml
volum
compar
control
ml
volum
median
histopatholog
raa
control
dog
show
small
amount
interstitialcollagen
singl
adipocyt
contrast
raa
dog
affect
af
andwithout
evid
dcm
mild
moder
multifoc
diffus
myocardi
fibrosi
diffus
infiltr
adipocyt
statist
signific
differ
normal
heart
gener
fibrosi
number
adipocyt
significantli
increas
raa
compar
laa
group
af
fibrosi
accumul
adipocyt
within
myocardium
describ
toresult
electr
inhomogen
predispos
arrhythmiaon
cellular
level
right
atrial
fibrosi
adipocyt
accumul
might
chang
respons
develop
atrial
fibril
atrial
dilat
breed
dog
except
high
preval
af
dcm
asynchron
ventricular
contract
caus
deterior
cardiac
function
reduc
respons
medic
therapi
peopl
heart
diseas
variou
echocardiograph
techniqu
use
human
evalu
left
ventricular
lv
synchron
order
assess
whether
cardiac
resynchron
therapi
crt
would
benefici
prior
studi
use
tissu
doppler
imag
tdi
deriv
strain
imag
detect
lv
dyssynchron
doberman
pinscher
dilat
cardiomyopathi
dcm
newer
imag
modal
speckl
track
strain
analysi
effect
detect
lv
dyssynchroni
human
techniqu
previous
evalu
doberman
pinscher
dcm
studi
therefor
aim
evalu
lv
synchroni
doberman
pinscher
dcm
use
speckl
track
strain
clientown
doberman
pinscher
includ
standard
echocardiographi
use
evalu
systol
function
left
ventricular
dimens
order
categor
dog
normal
abnorm
depend
systol
diastol
ventricular
dimens
eject
fraction
andor
shorten
fraction
oper
blind
echocardiograph
diagnosi
dog
paramet
measur
triplic
radial
rs
circumferenti
strain
cs
use
right
parastern
short
axi
level
papillari
muscl
calcul
synchroni
assess
measur
differ
qr
onset
timetopeak
strain
septal
anterior
posterior
left
ventricular
segment
evalu
differ
group
nest
effect
anova
beat
within
group
perform
p
consid
signific
base
echocardiograph
paramet
mention
dog
consid
normal
dcm
signific
differ
found
time
peak
rs
p
normal
dog
dog
affect
dcm
mean
time
peak
rs
ms
normal
dog
ms
dog
dcm
time
peak
cs
exhibit
signific
differ
group
p
ms
normal
dog
ms
dog
dcm
result
studi
show
delay
anteroseptaltoposterior
wall
peak
radial
strain
greater
doberman
pinscher
dcm
normal
dog
studi
would
requir
evalu
whether
differ
synchroni
dog
occult
stage
overt
dcm
ventricular
dyssynchroni
could
neg
affect
systol
dysfunct
peopl
crt
may
therefor
help
treatment
doberman
dcm
patent
ductu
arteriosu
often
treat
intraarteri
coilembol
implant
amplatz
canin
ductocclud
procedur
arteri
access
necessari
high
risk
develop
fatal
hemorrhag
arteri
punctur
site
remov
largebor
introduc
sheath
upon
complet
intervent
cardiologist
gener
use
surgic
cutdown
subsequ
ligat
femor
arteri
instead
percutan
arteri
punctur
use
selding
techniqu
effect
commerci
avail
chitosan
patch
test
experiment
dog
approv
institut
ethic
committe
first
beagl
committe
requir
termin
experi
select
appropri
introducersheath
ie
smaller
arteri
diamet
femor
arteri
first
imag
ultrasound
gener
anesthesia
introducersheath
place
femor
arteri
use
selding
techniqu
remov
chitosanpatch
appli
wound
accord
manufactur
instruct
manual
pressur
dog
monitor
direct
arteri
blood
pressur
measur
ecg
puls
oxymetri
capnographi
dog
kept
gener
anesthesia
sever
hour
leg
move
vigor
everi
minut
mimic
movement
awak
anim
macroscop
hemorrhag
notic
punctur
site
sign
sever
subcutan
bleed
suspect
blood
pressur
heart
rate
remain
stabl
sever
hour
dog
euthan
shown
effect
work
chitosanpatch
permiss
grant
surviv
experi
beagl
dog
one
femor
arteri
punctur
introduc
whose
thick
exceed
diamet
femor
arteri
dog
uncontrol
subcutan
hemorrhag
occur
immedi
manual
compress
time
sever
drop
blood
pressur
develop
tachycardia
dog
euthan
anesthesia
anoth
beagl
size
introduc
smaller
diamet
arteri
relev
hemorrhag
took
place
dog
recov
procedur
without
complic
similarli
good
outcom
found
two
boerboel
pilot
studi
conclud
chitosanpatch
effect
control
hemorrhag
femor
arteri
punctur
site
introducersheath
thinner
arteri
lumen
use
selding
techniqu
allow
less
invas
quicker
cardiac
catheter
preserv
femor
arteri
leg
blood
suppli
repeat
intraarteri
intervent
object
examin
longitudin
chang
echocardiograph
left
heart
chamber
dimens
cardiomyopathi
classif
cat
primari
myocardi
diseaseclin
record
review
cat
echocardiograph
examin
least
month
apart
diagnosi
primari
myocardi
diseas
studi
cat
left
heart
chamber
dimens
measur
singl
blind
train
observ
random
order
cardiomyopathi
type
classifi
accord
predefin
criteria
pair
comparison
made
use
wilcoxon
sign
rank
test
fisher
exact
cat
met
inclus
criteria
cardiomyopathi
type
entri
consist
hypertroph
cardiomyopathi
hcm
dilat
cardiomyopathi
dcm
arrhythmogen
right
ventricular
cardiomyopathi
arvc
normal
cat
overal
median
left
ventricular
lv
diastol
diamet
median
long
axi
left
atrial
la
diamet
increas
respect
wherea
lv
diastol
wall
thick
lv
fraction
shorten
chang
chang
dimens
seen
direct
chang
cardiomyopathi
type
document
cat
hcm
normal
normal
hcm
hcm
endomyocardi
form
restrict
cardiomyopathyth
inclus
criteria
led
bia
toward
clinic
stabl
cat
hcm
despit
chang
cardiomyopathi
phenotyp
observ
either
criteria
differ
felin
cardiomyopathi
defin
precis
phenotyp
express
cat
cardiomyopathi
chang
time
transesophag
echocardiographi
tee
proven
use
evalu
patent
ductu
arteriosu
pda
morpholog
therebi
guid
appropri
devic
select
addit
tee
combin
fluoroscopi
use
guid
transcathet
coil
embol
deploy
amplatz
canin
ductal
occlud
acdo
dog
recent
describ
use
transthorac
echocardiographi
tte
guidanc
transcateth
pda
occlus
acdo
without
use
fluoroscopi
observ
problem
deploy
patient
suboptim
acoust
window
howev
tee
overcom
issu
suboptim
tte
acoust
window
provid
higher
imag
resolut
cardiac
vascular
region
therefor
hypothes
tee
could
use
success
visual
vascular
structur
intervent
devic
safe
perform
pda
occlus
acdo
without
requir
fluoroscopyw
recruit
dog
patent
ductu
arteriosu
pda
teeguid
percutan
ductal
occlus
acdo
dog
anesthet
posit
right
later
recumb
right
femor
arteri
access
percutan
modifi
selding
techniqu
tee
probe
advanc
midesophag
posit
minim
forc
obtain
long
axi
view
transvers
plane
probe
retroflex
withdrawn
cranial
esophag
posit
cross
section
descend
aorta
seen
visual
pda
probe
slightli
straighten
turn
counterclockwis
ultrason
beam
orient
degreesin
dog
guid
wire
long
introducersheath
guid
aorta
pda
main
pulmonari
arteri
tee
monitor
acdo
advanc
introducersheath
flat
distal
disk
visual
within
main
pulmonari
arteri
tee
monitor
distal
disk
posit
pulmon
ostium
coupl
proxim
disk
deploy
within
ductal
ampulla
monitor
tee
visualizationth
guid
wire
long
introducersheath
acdo
appear
hyperecho
tee
imag
tee
guidanc
provid
imag
suffici
qualiti
clearli
monitor
procedur
realtim
realtim
monitor
also
allow
immedi
correct
guid
wire
cathet
devic
posit
procedur
success
without
complic
patientsw
demonstr
tee
monitor
like
tte
monitor
guid
everi
step
transcathet
acdo
embol
procedur
without
requir
fluoroscopi
therebi
avoid
radiat
exposur
provid
altern
ttebas
guidanc
especi
tte
visual
pda
insuffici
safe
time
acdo
deploy
right
ventricular
rv
dysfunct
occur
human
patient
leftsid
cardiac
disord
mechan
ventricular
interdepend
doppler
echocardiograph
indic
diastol
function
right
ventricl
good
prognost
marker
left
ventricular
lv
failur
secondari
ischem
dilat
cardiomyopathyth
aim
present
studi
assess
lv
rv
diastol
function
convent
doppler
pulsedwav
tissu
doppler
imag
pwtdi
dog
mitral
valv
diseas
mvd
without
pulmonari
hypertens
ph
test
echocardiograph
paramet
lv
rv
diastol
dysfunct
correl
dopplerestim
pulmonari
arteri
systol
pressur
pasp
dog
prospect
evalu
includ
dog
mvd
dog
complet
echocardiograph
evalu
carri
dog
mvd
divid
group
accord
acvim
classif
heart
failur
use
cutoff
valu
tricuspid
regurgit
tr
peak
veloc
ms
presenc
absenc
ph
consid
standard
echocardiograph
mitral
tricuspid
doppler
paramet
e
wave
wave
pwtdi
paramet
systol
wave
sa
earli
diastol
wave
e
late
diastol
wave
ea
ratio
ee
ratio
later
septal
mitral
annulu
later
tricuspid
annulu
measur
echocardiograph
data
compar
use
anova
multipl
contrast
ttest
bonferroni
correct
relationship
leftsid
echocardiograph
paramet
rv
diastol
paramet
examin
correl
analysi
correl
pasp
lv
rv
diastol
paramet
examin
multipl
linear
regress
valu
p
consid
significantdog
classifi
follow
healthi
dog
dog
class
dog
class
dog
class
c
differ
found
among
group
regard
rv
convent
doppler
pwtdi
paramet
howev
signific
weak
correl
found
leftsid
echocardiograph
paramet
left
atrial
dimens
end
diastol
end
systol
volum
index
peak
e
wave
wave
veloc
e
ratio
rv
pwtdi
paramet
ph
diagnos
dog
dog
deem
without
ph
dog
ph
significantli
differ
transmitr
e
wave
peak
veloc
ee
ratio
later
septal
mitral
annulu
two
latter
paramet
also
correl
pasp
r
respect
find
highlight
import
consid
ventricular
interdepend
dog
mvd
particularli
ph
cardiac
cycl
left
ventricl
lv
undergo
complex
deform
consist
overal
shorten
accompani
increas
wall
thick
twist
due
helic
orient
myocardi
fiber
use
speckl
track
echocardiographi
ste
circumferenti
strain
cs
well
twist
motion
lv
calcul
net
differ
lv
apic
basal
rotat
angl
cardiac
cycl
quantifi
postprocess
short
axi
imag
lv
thu
aim
studi
evalu
global
cs
twist
motion
smallmedium
size
dog
vari
sever
mr
attribut
myxomat
mitral
valv
diseas
mmvd
use
vividi
ultrasound
system
dog
underw
echocardiographi
includ
parastern
short
axi
view
basal
apic
level
offlin
analysi
rotat
midpapillari
muscl
level
analysi
global
cs
use
commerci
avail
softwar
echopac
twist
motion
systol
twist
sy
earli
untwist
earli
late
untwist
late
diastol
calcul
well
rate
comput
time
deriv
furthermor
time
onset
untwist
calcul
start
electromechan
activ
peak
twist
sy
measur
associ
twist
untwist
variabl
global
cs
convent
echocardiograph
indic
mr
sever
lv
remodel
examin
multipl
linear
regress
analys
includ
dog
characterist
heart
rate
hr
sex
breed
bodi
weight
age
global
cs
increas
increas
mr
p
untwist
earli
p
rate
p
also
increas
increas
mr
albeit
covari
certain
baselin
dog
characterist
time
onset
untwist
increas
mr
p
left
atrium
aortic
root
ratio
p
lv
intern
diamet
diastol
p
conclus
untwist
earli
global
cs
gradual
increas
onset
untwist
appear
delay
increas
mr
sever
smallmedium
size
dog
spontan
mmvd
hyperdynam
stage
delay
untwist
may
repres
lv
adapt
load
condit
mmvd
might
also
indic
midand
subepicardi
compens
earli
lv
dysfunct
reflect
delay
onset
relax
time
contractionrelax
cross
vulner
period
myocardi
fiber
mechan
systol
anterior
motion
sam
mitral
valv
mechan
correl
left
ventricular
outflow
tract
dynam
obstruct
lvotdo
associ
hypertroph
cardiomyopathi
hcm
instanc
howev
sam
without
left
ventricular
hypertrophi
regress
hypertrophi
increasingli
recognisedth
echocardiograph
studi
cat
diagnos
sam
without
hcm
cat
sam
regress
hypertrophi
cat
review
evalu
anatom
mechan
alter
contribut
lvotdo
ventriculoaort
aortosept
malalign
suggest
significantli
narrow
aortomitr
aortosept
angl
compar
group
control
cat
versu
p
versu
p
anatom
alter
lvot
constitu
includ
fals
tendon
insert
septal
crest
basal
septal
angul
apic
displac
posteromedi
anterolater
papillari
muscl
bifidaccessori
papillari
muscl
aberr
chordal
insert
septal
crest
sever
papillari
muscl
hypertrophi
thicken
aortic
cusp
subaort
ancillari
echo
mechan
lvotdo
includ
obstruct
mitral
septal
leaflet
protrus
displac
papillari
muscl
imping
angul
basal
septum
lvot
mechan
lvot
narrow
hypertroph
papillari
muscl
basal
septal
imping
lvot
associ
apic
balloon
without
obviou
apic
akinesisout
cat
lvotdo
without
hypertrophi
followup
studi
cat
respond
posit
atenolol
treatment
cat
initi
hypertrophi
revers
remodel
normalis
aortic
eject
veloc
within
month
month
atenolol
treatment
initi
cat
develop
aortic
regurgitationthes
data
indic
sam
exclus
relat
hcm
may
caus
complic
left
ventricular
hypertrophi
therapi
delay
onset
congest
heart
failur
chf
dog
dmvd
risk
diseas
progress
would
clinic
benefici
increas
laao
lveddn
serum
ntprobnp
ctni
concentr
associ
decreas
surviv
time
activ
reninangiotensinaldosteron
system
implic
cardiac
remodel
canin
dmvd
hypothesis
administr
spironolacton
dog
compens
dmvd
demonstr
risk
factor
would
reduc
rate
cardiac
remodel
associ
progress
dmvd
dog
acvim
class
b
dmvd
recruit
random
blind
placebocontrol
pilot
studi
dog
receiv
medic
cardiac
diseas
dog
demonstr
least
one
follow
risk
factor
echocardiograph
evid
cardiomegali
ntprobnp
ctni
dog
evid
cardiac
diseas
renal
diseas
hypoadrenocortic
hyperkalaemia
hyponatraemia
dog
random
receiv
spironolacton
oral
placebo
sid
month
comparison
group
made
use
mannwhitney
test
repeat
measur
linear
model
construct
compar
rate
chang
variabl
time
signific
set
p
data
analys
base
intent
treat
twenti
dog
vari
breed
enrol
ten
dog
demonstr
risk
factor
dog
risk
factor
dog
risk
factor
ten
dog
receiv
placebo
age
rang
year
mean
year
bodi
weight
rang
one
dog
group
die
suddenli
progress
chf
receiv
suboptim
spironolacton
dosag
ntprobnp
significantli
higher
spironolacton
group
baselin
ntprobnp
laao
lveddn
increas
time
placebo
spironolacton
group
rate
chang
ntprobnp
laao
lveddn
approach
reach
signific
differ
group
conclus
treatment
spironolacton
might
slow
rate
increas
cardiac
size
dog
acvim
class
b
dmvd
show
risk
factor
poor
outcom
decreas
rate
increas
cardiac
size
might
delay
onset
chf
studi
warrant
investig
hypothes
cardiac
dysfunct
concern
human
system
inflammatori
respons
syndrom
sir
patient
increas
cardiac
biomark
decreas
cardiac
function
alreadi
describ
previou
canin
sir
studi
increas
cardiac
biomark
ntprobnp
ctnt
lactat
prognost
valu
establish
present
studi
evalu
kinet
basic
echocardiograph
paramet
fraction
shorten
fs
left
ventricular
eject
fraction
lvef
reflect
systol
function
ratio
left
atrium
aorta
laao
reflect
preload
canin
sir
hypothes
fs
lvef
laao
alter
canin
sir
paramet
carri
prognost
informationdog
sir
without
primari
cardiac
diseas
present
emerg
servic
prospect
includ
januari
august
cardiac
ultrasonographi
perform
two
veterinarian
standard
fashion
initi
present
hour
hospit
discharg
death
control
visit
one
month
discharg
dog
classifi
accord
underli
diseas
process
infect
neoplasia
trauma
gastricdil
volvulu
gdv
gi
diseas
miscellan
diseas
statist
analysi
perform
sa
univari
analysi
use
assess
normal
distribut
mix
procedur
logist
procedur
perform
accordingli
p
thirti
seven
dog
infect
neoplasia
trauma
gdv
gi
miscellan
diseas
includ
twentyeight
patient
surviv
die
euthanasia
financi
reason
euthanasia
prognost
reason
eleven
dog
control
visit
owner
declin
control
echocardiographi
patient
lost
followup
die
control
visit
fs
laao
significantli
correl
surviv
discharg
howev
lvef
addit
lvef
fs
chang
significantli
hospit
neither
compar
laao
howev
increas
significantli
hospit
laao
differ
significantli
valu
unexpectedli
surviv
dog
lower
fs
nonsurvivor
laao
associ
surviv
increas
rapidli
hospit
valu
similar
probabl
reflect
efficaci
fluid
therapi
emerg
casesin
popul
canin
sir
patient
echocardiograph
evid
cardiac
dysfunct
demonstr
report
firstopinion
practic
felin
arteri
thromboembol
ate
scarc
aim
describ
evalu
outcom
cat
ate
present
three
firstopinion
clinicsclin
record
cat
present
ate
review
histori
clinic
find
presenc
congest
heart
failur
chf
outcom
kaplanmei
log
rank
analysi
perform
evalu
associ
survivaldur
studi
period
cat
present
ate
overal
felin
incid
cat
male
nonpedigre
sign
cardiovascular
diseas
prior
ate
includ
cardiomyopathi
heart
murmur
gallop
soundarrhythmia
hyperthyroid
cat
present
within
hour
clinic
sign
median
age
present
atrioventricular
block
avb
arrhythmia
result
conduct
abnorm
atrioventricular
node
lead
sever
sign
sudden
deathth
aim
studi
evalu
longterm
intrins
rhythm
variat
dog
undergon
pacemak
pm
implant
ninetytwo
dog
differ
breed
rd
degre
avb
advanc
nd
degre
avb
paroxysm
avb
atrial
fibril
retrospect
analyz
fortynin
male
femal
mean
age
sd
year
mean
bodi
weight
kg
intrins
rhythm
evalu
day
pm
implant
day
confid
interv
ci
day
ci
day
ci
day
ci
accord
avb
grade
differ
control
rhythm
disturb
consid
advanc
regress
unchang
shapirowilk
kolmogorovsmirnov
test
use
test
normalci
ftest
compar
mean
gener
linear
model
chisquar
examin
associ
categor
variabl
statu
control
sixti
dog
intrins
rhythm
chang
avb
progress
avb
regress
fortyeight
case
remain
unchang
regress
sinu
rhythm
avb
advanc
eight
advanc
second
degre
avb
progress
complet
avb
regress
sinu
rhythm
avb
remain
unchang
five
paroxysm
progress
complet
avb
avb
remain
unchang
four
avb
progress
complet
avb
regress
sinu
rhythm
remain
unchang
avb
atrial
fibril
remain
unchang
chisquar
test
show
chang
intrins
rhythm
associ
type
avb
v
p
time
control
v
p
factor
statist
signific
regress
occur
within
day
progress
occur
time
result
show
degre
avb
moment
pm
implant
consid
definit
diagnosi
sinc
case
could
present
progress
regress
potenti
progress
pm
implant
consid
first
choic
treatment
also
case
low
studi
need
evalu
caus
transitori
high
grade
avb
tissu
doppler
imag
tdi
complement
convent
echocardiographi
assess
myocardi
function
aim
studi
investig
breed
differ
intraobservervari
colour
tdi
variabl
healthi
dogsfiftythre
privatelyown
male
dog
prospect
recruit
dog
declar
healthi
physic
examin
blood
pressur
measur
ecg
analys
urin
blood
haematolog
biochemistri
convent
echocardiograph
doppler
examin
part
eufund
lupaproject
directli
follow
extens
examin
tdi
acquisit
perform
experienc
echocardiograph
use
philip
small
dog
larg
dog
mhz
probe
cineloop
acquir
right
shortaxi
view
radial
colour
tdi
variabl
endocardium
epicardium
left
ventricular
free
wall
later
analys
six
healthi
dog
includ
substudi
aim
evalu
effect
sourc
variat
use
hierarchi
randomeffect
modelten
examin
dog
exclud
due
breath
artifact
poor
qualiti
curv
leav
dog
studi
labrador
retriev
cavali
king
charl
spaniel
dachshund
mean
age
year
sd
pvalu
consid
signific
statist
analys
kruskalw
oneway
analysi
varianc
show
labrador
retriev
significantli
higher
valu
endocardi
epicardi
systol
wave
longer
time
peak
endocardi
epicardi
eand
awav
compar
two
breed
labrador
retriev
also
significantli
lower
heart
rate
hr
analysi
breed
differ
use
multipl
regress
analysi
show
major
effect
bodi
weight
hr
endocardi
epicardi
wave
time
peak
endocardi
epicardi
eand
awav
primarili
affect
hr
dog
varianc
compon
major
effect
variabl
tdi
variablesin
conclus
time
peak
diastol
wave
longer
labrador
retriev
compar
smallbre
dog
furthermor
higher
swave
valu
labrador
retriev
might
indic
differ
contractil
pattern
largebre
dog
warrant
investig
mitral
regurgit
mr
common
heart
diseas
dogsdog
advanc
stage
diseas
like
develop
pulmonari
edema
heart
failur
aim
studi
evalu
plasma
creactiv
protein
crp
concentr
dog
underw
mitral
valv
repair
mrall
dog
oper
octob
octob
dog
categor
accord
intern
small
anim
cardiac
health
council
isachc
classif
physic
examin
thorac
radiographi
color
flow
doppler
echocardiographi
perform
surgeri
plasma
crp
concentr
white
blood
cell
count
also
determin
surgeri
cardiogen
pulmonari
edema
diagnos
basi
clinic
examin
thorac
radiographyoveral
dog
mean
bodi
weight
kg
mean
age
year
enrol
dog
cardiogen
pulmonari
edema
dog
breed
chihuahua
n
cavali
king
charl
spaniel
n
maltes
n
yorkshir
terrier
n
shih
tzu
n
miniatur
dachshund
n
other
n
signific
differ
found
age
bodi
weight
vertebr
heart
size
laao
ratio
significantli
decreas
surgeri
compar
preoper
valu
oper
crp
concentr
white
blood
cell
count
isachc
class
iiib
dog
mgdl
respect
higher
class
ib
mgdl
respect
class
ii
mgdl
respect
class
iiia
mgdl
respect
dog
addit
crp
concentr
white
blood
cell
count
class
iiib
dog
significantli
decreas
surgeri
compar
preoper
valu
crp
concentr
white
blood
cell
count
dog
cardiogen
pulmonari
edema
significantli
increas
compar
nonpulmonari
edema
furthermor
cardiogen
pulmonari
edema
disappear
within
month
surgeri
crp
concentr
white
blood
cell
count
becam
normalin
conclus
crp
concentr
increas
dog
mr
cardiogen
pulmonari
edema
wide
recogn
inflammatori
reaction
play
key
role
develop
heart
failur
consequ
data
indic
import
strict
manag
pulmonari
edema
inflamm
neurotransmitt
serotonin
recent
suggest
role
develop
myxomat
mitral
valv
diseas
mmvd
dogsth
aim
studi
investig
whether
serum
concentr
associ
mmvd
sever
dog
assess
potenti
associ
serum
concentr
dog
characterist
echocardiograph
variabl
heart
rate
systol
blood
pressur
platelet
size
mean
platelet
volum
studi
clientown
dog
natur
acquir
mmvd
vari
sever
prospect
recruit
studi
dog
classifi
accord
mmvd
sever
breed
predispos
earli
onset
mmvd
without
echocardiograph
evid
diseas
mild
moder
sever
diseas
serum
concentr
analyz
use
elisa
assaylow
serum
concentr
shown
dog
sever
mmvd
compar
dog
predispos
mmvd
p
dog
mild
mmvd
p
unilinear
multipl
regress
analys
show
serum
concentr
decreas
increas
left
atrial
aortic
root
ratio
laao
higher
cavali
king
charl
spaniel
ckc
dog
compar
dog
breed
higher
femal
dog
male
dog
laao
variabl
strongli
associ
serum
concentrationin
conclus
find
higher
serum
concentr
dog
predispos
mmvd
ckc
dog
mild
mmvd
suggest
alter
signal
might
play
role
progress
earli
stage
mmvd
hypersomatotrop
hs
common
reason
develop
diabet
mellitu
cat
remiss
diabet
achiev
accur
diagnosi
hs
although
diagnosi
hamper
rel
complex
confirm
hs
requir
combin
insulin
growth
felin
growth
hormon
measur
intracrani
imag
unfortun
three
limit
diagnost
aid
evalu
success
therapi
particularli
radiotherapi
rt
consequ
precis
marker
hs
requir
current
studi
aim
evalu
physiolog
behaviour
diagnost
potenti
serum
ghrelin
felin
hs
ghrelin
endogen
ligand
gh
secretagogu
receptor
hypothesis
product
ghrelin
might
suppress
hs
subnorm
serum
level
could
marker
increas
gh
activityfast
preinsulin
serum
sampl
collect
normal
age
match
control
uncompl
diabet
dm
hypersomatotroph
diabet
hsdm
cat
cat
categor
hsdmgroup
basi
elev
demonstr
pituitari
lesion
imag
cat
addit
serum
sampl
obtain
follow
rt
cat
categor
dmgroup
basi
low
normal
insulin
requir
iukg
serum
ghrelin
determin
use
total
ghrelin
elisa
system
valid
cat
data
test
normal
concentr
compar
group
use
unpair
ttest
pair
ttest
rt
hsdmgroupsserum
total
ghrelin
differ
hsdm
dmgroup
signific
differ
present
control
group
hsdm
dmgroup
serum
ghrelin
concentr
hsdm
cat
undergo
rt
n
significantli
higher
follow
complet
treatment
versu
result
suggest
felin
serum
total
ghrelin
suppress
similar
level
diabet
diabet
hypersomatotroph
state
compar
healthi
subject
consequ
appear
serum
ghrelin
level
help
determin
presenc
hs
diabet
cat
howev
result
indic
treatment
hs
rt
result
increas
serum
ghrelin
suggest
presenc
independ
inhibitori
effect
excess
gh
serum
ghrelin
product
potenti
inhibitori
effect
gh
might
render
serum
ghrelin
measur
use
addit
tool
assess
hypersomatotroph
remiss
rt
studi
howev
indic
date
studi
character
histopatholog
featur
endocrin
exocrin
pancrea
cat
diabet
mellitu
loss
bcell
consist
find
detail
data
presenc
type
inflammatori
cell
avail
recent
observ
hyperglycemia
increas
neutrophil
exocrin
pancrea
aim
present
studi
assess
whether
diabet
cat
patholog
evid
islet
inflamm
pancreat
defin
islet
lesion
comparison
wellmatch
control
populationformalinfix
paraffinembed
pancreat
sampl
collect
postmortem
examin
perform
diabet
control
cat
die
due
diseas
clinic
small
anim
intern
medicin
univers
zurich
switzerland
control
cat
select
match
age
sex
breed
bodi
weight
section
routin
stain
hematoxilineosin
doublelabel
immunohistochemistri
perform
follow
marker
insulin
myeloperoxidas
neutrophil
insulin
tlymphocyt
insulin
blymphocyt
insulin
pcna
prolifer
marker
glucagon
prolifer
marker
lightmicroscop
cell
count
morphometr
analys
perform
manual
softwar
imagej
respect
data
analyz
conting
tabl
tteststhirtyseven
diabet
cat
control
includ
mean
insulinposit
cross
section
area
approxim
lower
diabet
control
cat
p
glucagon
similar
prolifer
insulinposit
glucagonposit
cell
averag
count
neutrophil
tand
blymphocyt
islet
differ
group
interestingli
presenc
b
lymphocyt
gener
tend
frequent
diabet
control
cat
exocrin
pancrea
trend
toward
increas
presenc
necrosi
fibrosi
observ
diabet
cat
vs
inflammatori
infiltr
differ
prolifer
acinar
cell
increas
diabet
cat
p
notabl
nearbi
islet
p
result
confirm
previou
observ
loss
bcell
occur
diabet
cat
addit
subset
diabet
cat
show
lymphocyt
infiltr
islet
might
contribut
bcell
loss
increas
necrosi
fibrosi
exocrin
tissu
may
suggest
diabet
lead
pancreat
cat
increas
prolifer
rate
acinar
cell
deserv
investig
human
find
associ
chronic
pancreat
well
transdifferenti
islet
cell
basi
rel
high
preval
hypersomatotrop
hs
amongst
cat
diagnosi
diabet
mellitu
well
possibl
subtl
phenotyp
patient
signific
implic
prognosi
treatment
screen
diabet
cat
hs
could
advoc
veterinarian
serum
total
insulinlik
growth
assess
repres
feasibl
access
mean
perform
screen
howev
hepat
product
depend
presenc
suffici
portal
insulin
defici
newli
diagnos
diabet
cat
result
fals
neg
result
addit
elev
report
nonacromegal
diabet
cat
altern
addit
diagnost
test
hs
well
evalu
success
treatment
hs
therefor
desir
sinc
felin
hs
associ
tissu
growth
serum
type
iii
procollagen
propeptid
piiip
peripher
indic
collagen
turnov
hypothesis
use
indic
activ
diseas
growth
hormon
bioactiv
fast
preinsulin
serum
sampl
prospect
collect
uncompl
diabet
dm
hypersomatotroph
diabet
hsdm
cat
cat
categoris
hsdmgroup
basi
elev
radioimmunoassay
ngml
follow
demonstr
pituitari
lesion
intracrani
imag
dmgroup
basi
low
ngml
modest
insulin
requir
iukg
elisa
system
piiip
develop
use
cat
data
test
normal
concentr
compar
use
mann
whitney
test
correl
serum
assess
calcul
spearman
correl
coeffici
rho
dilut
parallel
use
cat
serum
high
low
piiipact
indic
valid
elisa
system
intraassay
coeffici
variat
calcul
prove
adequ
precis
high
low
concentr
assay
detect
limit
found
ngml
median
serum
piiip
ngml
rang
hsdm
group
versu
rang
dm
group
p
signific
correl
serum
piiip
p
conclus
serum
piiip
measur
cat
addit
serum
piiip
seem
altern
measur
growth
hormon
bioactiv
cat
given
signific
elev
concentr
felin
hs
evalu
piiip
case
hs
help
determin
exact
ad
valu
evalu
paramet
diagnosi
hs
well
assess
treatment
efficaci
glucos
galactos
transport
across
brush
border
membran
bbm
enterocyt
sodiumglucos
code
sole
rout
intestin
glucos
absorpt
level
express
dictat
bbm
transport
capac
glucos
relev
express
predisposit
diabet
mellitu
obes
investig
dog
aim
assess
effect
promot
function
known
snp
flank
region
canin
search
novel
snp
well
defin
sampl
dog
vari
risk
diabet
obes
cell
shown
express
vitro
fragment
canin
flank
region
rel
transcript
start
site
clone
canin
genom
dna
ligat
basic
plasmid
bear
firefli
luciferas
report
gene
use
transient
transfect
cell
shown
drive
luciferas
product
significantli
control
p
determin
effect
three
known
snp
region
promot
function
new
promoterreport
construct
possibl
permut
three
snp
creat
use
sitedirect
mutagenesi
construct
use
transient
transfect
cell
use
renilla
luciferas
intern
control
signific
differ
promot
function
seen
suggest
three
snp
signific
effect
constitut
transcript
mrna
dogsa
search
novel
snp
region
dog
made
two
breed
predispos
diabet
mellitu
samoy
cairn
terrier
two
breed
rare
develop
diabet
boxer
german
shepherd
dog
two
breed
predispos
obes
labrador
retriev
cocker
spaniel
genom
dna
healthi
individu
breed
obtain
uk
companion
anim
dna
archiv
kind
permiss
flank
region
amplifi
individu
highfidel
pcr
use
breedlabel
primer
gel
purifi
mix
equimolar
amount
sequenc
pyrosequenc
sequenc
gs
flx
roch
sequenc
flank
region
individu
breed
test
ident
evid
variat
promot
sequenc
dog
influenc
pathogenesi
diabet
obes
breed
remiss
diabet
mellitu
may
achiev
cat
remiss
occur
recoveri
bcell
function
possibl
bcell
mass
requir
novel
class
antidiabet
drug
act
via
incretin
system
increas
bcell
prolifer
glucosestimul
insulin
secret
rodent
two
strategi
incretinbas
therapi
analogu
eg
exenatid
shortact
exsa
exenatid
longact
exla
inhibitor
eg
sitagliptin
success
use
human
diabet
knowledg
use
incretin
cat
scarc
demonstr
exsa
inhibitor
increas
insulin
secret
intraven
glucos
stimul
healthi
cat
effect
drug
meal
stimul
use
exla
explor
cat
farth
aim
studi
test
whether
exsa
byetta
sc
exla
bydureon
sc
sitagliptin
januvia
po
safe
use
cat
identifi
effect
drug
dose
doseescal
studynin
healthi
cat
use
exsa
given
cat
lgkg
consecut
day
exla
given
cat
lg
kg
singl
inject
sitagliptin
given
cat
mgkg
consecut
day
washout
period
week
allow
dose
day
treatment
block
meal
respons
test
mrt
perform
cat
h
fastbi
feed
daili
energi
intak
subsequ
blood
sampl
timepoint
minut
insulin
glucos
area
curv
auc
calcul
drug
dosegastrointestin
side
effect
day
durat
observ
cat
group
irrespect
dose
wellb
appetit
otherwis
conserv
exsa
increas
insulin
auc
respect
compar
insulin
auc
mrt
without
drug
administr
exla
sitagliptin
increas
insulin
auc
respect
auc
glucos
similar
cat
irrespect
drug
dose
conclud
exsa
exla
sitagliptin
safe
use
healthi
cat
exsa
increas
insulin
secret
effect
exla
sitagliptin
insulin
detemir
synthet
long
act
insulin
analogu
design
maintain
basal
level
insulin
human
diabet
mellitu
dm
pharmacokinet
studi
dog
indic
insulin
detemir
greater
effect
type
insulin
requir
lower
dose
object
studi
evalu
efficaci
frequenc
hypoglycemia
dog
dm
treat
insulin
detemir
eight
dog
includ
studi
median
rang
age
year
femal
intact
spay
intact
male
median
rang
bodi
weight
dog
relev
concurr
diseas
eg
hypothyroid
hypercortisol
neoplasia
renal
insuffici
dog
prior
administr
diabetogen
drug
exclud
dog
receiv
insulin
detemir
bid
least
month
reevalu
perform
week
includ
clinic
sign
blood
glucos
curv
bgc
fructosamin
concentr
median
rang
insulin
dose
ukg
bid
admiss
significantli
differ
week
therapi
ukg
rang
initi
dog
markedli
elev
blood
glucos
mmoll
mmoll
elev
fructosamin
concentr
lmoll
lmoll
mean
glucos
concentr
mmoll
bgc
reevalu
median
rang
glucos
nadir
valu
mmoll
fructosamin
concentr
lmoll
respect
glucos
concentr
mean
significantli
p
lower
week
therapi
treatment
hypoglycemia
glucos
nadir
mmoll
consist
problem
identifi
dog
bgc
dog
episod
dog
owner
report
clinic
sign
lethargi
weak
unsteadi
gait
could
caus
hypoglycemia
base
owner
opinion
clinic
assess
veterinarian
bgc
month
therapi
good
control
diseas
obtain
moder
control
dog
accord
preliminari
result
insulin
detemir
effect
control
hyperglycemia
dog
dm
potent
type
insulin
also
use
bid
therefor
lower
dose
use
nevertheless
hypoglycemia
common
find
especi
small
dog
therefor
insulin
detemir
use
great
caution
dilut
could
consid
spontan
hypercortisol
due
acthindepend
hypersecret
cortisol
adrenocort
tumor
case
although
understand
growth
hormon
activ
at
expand
recent
year
pivot
factorsact
pathogenesi
remain
undisclosedth
canon
wntpathway
play
role
cell
surviv
cell
cycl
progress
shown
involv
mani
differ
tumor
type
includ
human
mous
at
central
pathway
cytoplasm
andor
nuclear
accumul
demonstr
human
cortisolsecret
at
partli
explain
mutat
exon
studi
activ
canon
wntpathway
investig
adren
adenoma
carcinoma
dog
acthindepend
hypercortisol
fifteen
normal
canin
adren
serv
control
tissu
mrna
express
measur
wntligand
wnt
wnt
wnt
wnt
wnt
variant
wnt
wnt
wnt
wntligand
inhibitor
dkk
wif
sfrp
wnt
target
gene
cmyc
addit
code
region
mrna
sequenc
local
evalu
immunohistochemistri
ihc
result
express
analysi
wntligand
wntligand
inhibitor
demonstr
signific
downregul
wnt
wnt
variant
wnt
target
gene
cyclin
significantli
downregul
adenoma
cmyc
axin
mrna
express
differ
at
normal
adrenalssequ
analysi
reveal
mutat
at
silent
mutat
probabl
singl
nucleotid
polymorph
snp
neutral
mutat
arginin
histidin
nonsens
mutat
result
prematur
stop
codon
delet
basepair
combin
neutral
mutat
amino
acid
chang
appear
tumorassoci
wherea
stop
codon
activ
mutat
ihc
demonstr
accumul
cytoplasm
part
at
nuclear
stain
rare
presentw
conclud
canon
wntpathway
like
involv
pathogenesi
canin
cortisolsecret
at
trilostan
treatment
choic
canin
pituitarydepend
hyperadrenocortic
pdh
howev
controversi
ideal
treatment
regim
object
studi
evalu
efficaci
safeti
sid
vs
bid
trilostan
treatment
canin
pdhthi
prospect
randomis
studi
includ
dog
pdh
dog
treat
trilostan
sid
initi
dose
hr
trilostan
bid
hr
histori
physic
exam
haemogram
biochem
profil
acth
stimul
test
urinari
cortisol
creatinin
ratio
uccr
perform
treatment
one
week
sid
hr
post
trilostan
bid
hr
month
treatment
hr
post
medic
median
daili
dose
throughout
studi
similar
dog
receiv
sid
mgkgday
bid
mgkgday
trilostan
baselin
cortisol
concentr
trilostan
five
reevalu
sid
group
bid
group
lgdl
baselin
cortisol
significantli
higher
sid
group
sixmonth
evalu
post
acth
cortisol
concentr
sid
group
bid
group
statist
signific
differ
found
evalu
uccr
dog
sid
group
bid
group
similarli
statist
signific
differ
found
throughout
studi
five
reevalu
time
clinic
sign
polyuria
polydipsia
andor
polyphagia
persist
dog
sid
group
persist
clinic
sign
occur
dog
bid
group
mild
advers
effect
occur
dog
treat
sid
bid
trilostan
respectivelybas
studi
conclud
result
acth
stimul
test
uccr
dog
pdh
treat
protocol
similar
reevalu
time
howev
clinic
sign
resolv
greater
proport
dog
receiv
trilostan
bid
use
trilostan
twice
daili
help
reduc
number
dog
good
clinic
respons
effect
trilostan
therapi
monitor
regular
acth
stimul
timeconsum
expens
therefor
monitor
system
without
stimul
protocol
less
client
expens
would
preferableth
aim
studi
twofold
firstli
evalu
baselin
cortisol
endogen
acth
cacth
baselin
cortisol
acth
ratio
cortisolacth
ratio
could
replac
acth
stimul
test
secondli
evalu
baselin
cortisol
provid
addit
inform
postacth
cortisol
alon
measur
could
abandonedfortyon
trilostanetr
dog
pdh
diagnos
april
decemb
includ
studi
total
acth
stimul
test
baselin
postacth
delta
cortisol
postacth
cortisol
minu
baselin
cortisol
cacth
result
cortisolacth
ratio
analyzedcontrol
adren
gland
function
classifi
accord
target
rang
postacth
cortisol
concentr
excess
nmoll
group
optim
nmoll
group
inadequ
nmoll
group
second
step
control
adren
gland
function
reclassifi
accord
baselin
cortisol
valu
new
classif
compar
origin
onether
signific
correl
baselin
cortisol
postacth
cortisol
signific
differ
baselin
cortisol
group
howev
larg
overlap
reclassif
adren
gland
function
basi
baselin
cortisol
reveal
misclassif
testsendogen
acth
correl
baselin
postacth
cortisol
differ
group
baselin
cortisol
acth
ratio
differ
significantli
group
group
larg
overlapto
determin
measur
baselin
cortisol
give
addit
inform
postacth
cortisol
alon
delta
cortisol
valu
analys
delta
cortisol
correl
significantli
postacth
cortisol
baselin
cortisol
differ
significantli
group
overlap
howev
largeth
larg
overlap
use
singl
valu
without
take
postacth
cortisol
consider
lead
unaccept
low
correct
differenti
control
adren
gland
function
therefor
acth
stimul
test
determin
postacth
cortisol
replac
baselin
cortisol
endogen
acth
cortisolacth
ratio
howev
baselin
cortisol
concentr
give
addit
inform
postacth
cortisol
alon
determin
abandon
human
recombin
human
thyrotropin
rhtsh
enhanc
radioact
iodin
uptak
raiu
patient
differenti
thyroid
cancer
properti
particularli
interest
dog
high
dose
use
treatment
diseas
studi
perform
veterinari
medicin
optim
treatment
thyroid
cancerth
aim
studi
evalu
effect
rhtsh
uptak
dog
thyroid
tumorsnin
dog
thyroid
neoplasia
includ
prospect
crossov
studi
six
dog
unilater
tumor
dog
bilater
tumor
dog
ectop
tumor
diagnosi
base
physic
examin
cytolog
cervic
scintigraphi
avail
histopatholog
dog
administ
baselin
raiu
determin
week
week
wash
period
week
dog
receiv
rhtsh
lg
iv
inject
patient
order
protocol
revers
scan
dog
receiv
mbq
iv
planar
scintigraphi
perform
thereaft
tumor
raiu
calcul
blood
sampl
taken
baselin
rhtsh
administr
measur
serum
total
thyroxin
serum
thyrotropin
tsh
concentrationsrhtsh
caus
statist
signific
chang
thyroid
tumor
raiu
despit
lack
overal
statist
signific
rhtsh
administr
raiu
increas
tumor
raiu
increas
tumor
increas
raiu
observ
uptak
rhtsh
rang
time
baselin
uptak
patient
postrhtsh
raiu
doubl
compar
baselin
raiu
raiu
thorac
metastas
patient
could
calcul
thorac
metastasi
raiu
doubl
rhtsh
raiu
decreas
rhtshin
euthyroid
patient
rhtsh
induc
signific
increas
concentr
confirm
biolog
activ
rhtshthi
studi
suggest
iv
administr
lg
rhtsh
inconsist
effect
thyroid
tumor
raiu
mark
increas
uptak
tumor
decreas
other
studi
necessari
determin
best
dosag
rout
time
rhtsh
optim
thyroid
tumor
raiuthi
studi
partli
fund
dutch
anim
cancer
foundat
transderm
methimazol
suggest
altern
treatment
option
hyperthyroid
cat
previou
studi
could
show
good
clinic
effect
pleuron
lecithin
organogel
plo
base
product
twicedaili
basi
reduc
dose
frequenc
known
improv
owner
complianc
howev
studi
yet
evalu
longterm
treatment
respons
daili
administrationobject
present
studi
assess
whether
daili
administr
transderm
methimazol
origin
formul
plo
effect
altern
twicedaili
treatment
followup
period
month
evalu
cours
period
methimazol
applic
select
catstwenti
clientown
cat
newli
diagnos
hyperthyroid
avail
followup
inform
includ
studi
methimazol
formul
plobas
vehicl
appli
pinna
inner
ear
start
dose
q
hour
cat
recheck
week
week
month
month
month
month
start
therapi
addit
cat
concentr
measur
everi
hour
gel
applic
hour
period
week
start
therapi
week
clinic
improv
observ
anim
chang
treatment
oral
medic
due
erythema
intern
pinna
ear
necessari
one
cat
none
anim
show
side
effect
followup
period
signific
decreas
concentr
determin
recheck
compar
pretreat
concentr
methimazol
dosag
increas
decreas
remain
unchang
cat
two
cat
decreas
dose
later
reincreas
one
cat
chang
hour
signific
chang
period
fluctuat
correspond
variat
precis
seriesthes
result
accord
previou
studi
use
twicedaili
regimen
could
show
daili
administr
transderm
methimazol
origin
formul
plo
effect
treatment
option
longterm
manag
felin
hyperthyroid
time
blood
sampl
gel
applic
import
assess
respons
treatment
increas
preval
larg
thyroid
tumor
intrathorac
thyroid
thyroid
scintigraphi
provid
valuabl
inform
regard
thyroid
anatomi
physiolog
play
integr
role
diagnosi
stage
manag
felin
thyroid
diseas
studi
perform
thyroid
imag
consecut
hyperthyroid
cat
refer
radioiodin
therapi
januari
decemb
scintigraphi
perform
part
stage
protocol
thyroid
volum
estim
dose
estim
vet
radiol
ultrasound
cat
locat
area
increas
radionuclid
uptak
iru
also
record
cervic
thorac
inlet
chest
final
scan
evalu
featur
suggest
malign
multipl
extens
area
iru
heterogen
pattern
iru
irregular
spicul
margin
extens
tumor
thorac
inlet
thorax
metastasi
region
lymph
node
lung
cat
recent
diagnos
cat
howev
interv
diagnosi
treatment
rang
year
almost
cat
receiv
longterm
antithyroid
drug
treatment
cat
divid
group
base
interv
diagnosi
treatment
group
year
cat
group
year
cat
group
year
cat
group
year
cat
group
year
cat
estim
thyroid
volum
group
cat
compar
progress
signific
p
increas
median
tumor
volum
occur
cm
group
cm
group
cm
group
cm
group
cm
group
preval
cat
area
iru
within
thorac
caviti
also
increas
progress
group
group
group
group
group
final
preval
suspect
thyroid
carcinoma
cat
also
increas
progress
group
group
group
group
group
contrast
increas
preval
ectop
thyroid
tissu
found
group
group
group
group
group
conclus
result
indic
hyperfunct
thyroid
tissu
continu
grow
enlarg
time
thyroid
carcinoma
extrem
rare
cat
recent
diagnos
hyperthyroid
preval
increas
dramat
time
suggest
transform
benign
diseas
common
cat
control
medic
measur
plasma
renin
activ
pra
consid
gold
standard
monitor
mineralocorticoid
substitut
human
primari
hypoadrenocortic
ph
sensit
paramet
reflect
insuffici
well
inappropri
high
replac
dog
ph
mineralocorticoid
substitut
current
monitor
mainli
serum
potassium
sodium
concentr
role
pra
monitor
mineralocorticoid
replac
investig
aim
studi
measur
compar
pra
dog
newli
diagnos
ph
dog
diseas
mimick
ph
evalu
pra
dog
ph
treat
differ
mineralocorticoid
substitut
regimesth
follow
group
dog
includ
studi
dog
newli
diagnos
ph
group
dog
alreadi
treat
ph
group
dog
diseas
mimick
ph
group
group
pra
measur
treatment
week
week
week
start
therapi
group
pra
measur
least
twice
everi
month
group
pra
measur
initi
present
three
dog
group
dog
group
treat
fludrocortison
florinef
bristolmy
squibb
two
dog
group
dog
group
treat
docp
percorten
v
novarti
pra
measur
enzymat
assay
via
trap
angiotensin
servic
dangiologi
chuvn
lausann
result
analys
mean
nonparametr
method
p
pra
treatment
significantli
higher
group
ng
lh
median
group
nglh
median
averag
pra
therapi
rang
ngmlh
median
pra
decreas
significantli
dog
treat
fludrocortison
pra
dog
treat
docp
ngmlh
median
significantli
lower
compar
dog
treat
fludrocortison
ngmlh
median
dog
treat
docp
normal
serum
sodium
potassium
recheck
wherea
dog
treat
fludrocortison
mild
sever
electrolyt
abnorm
sever
occas
weak
correl
pra
serum
potassiummeasur
pra
promis
tool
monitor
mineralocorticoid
substitut
dog
ph
accord
preliminari
result
docp
superior
fludrocortison
mineralocorticoid
replac
phenobarbit
wide
use
control
epilepsi
dog
use
phenobarbit
induc
hepat
enzym
activ
may
decreas
serum
total
free
thyroxin
exact
mechan
preval
phenomenon
unknown
aim
present
retrospect
studi
therefor
investig
mani
dog
treat
phenobarbit
show
decreas
thyroid
hormon
give
insight
potenti
mechan
tsh
measur
canin
serum
sampl
submit
assess
therapeut
concentr
phenobarbit
smaller
subset
dog
albumin
total
protein
transthyretin
ttr
also
measur
diagnost
center
popul
anim
health
michigan
usaaccord
thyroid
result
dog
classifi
non
thyroid
ill
nti
nmoll
pmoll
tsh
ngml
equivoc
e
nmoll
pmoll
tsh
ngml
hypothyroid
ht
pattern
low
tsh
ng
ml
normal
n
pmoll
tsh
ngml
fortyf
dog
classifi
nti
dog
classifi
e
classifi
ht
n
dog
fit
defin
categori
statist
signific
differ
mean
phenobarbit
concentr
nti
e
ht
n
lmoll
respect
twenti
dog
group
analyz
albumin
total
protein
compar
healthi
dog
receiv
phenobarbit
statist
signific
differ
notic
p
attempt
measur
ttr
concentr
via
commerci
avail
elisa
tsz
elisa
framingham
usa
gave
us
inconsist
perform
conclus
dog
phenobarbit
treatment
classifi
nti
group
e
would
includ
valu
could
high
neither
phenobarbit
total
protein
albumin
concentr
predict
valu
thyroid
hormon
concentr
studi
abl
defin
preval
phenomenon
dog
phenobarbit
therapi
low
thyroid
hormon
concentr
give
insight
pathogenesi
ideal
demonstr
hypothyroid
dog
receiv
phenobarbit
includ
assay
thyroid
hormon
tsh
pheochromocytoma
pheo
rare
malign
catecholaminesecret
tumor
adren
medulla
catecholamin
metanephrin
plasma
urin
approv
biomark
detect
diseas
human
howev
question
test
best
controversi
previous
demonstr
measur
urinari
catecholamin
metanephrin
creatinin
ratio
help
diagnosi
pheo
dog
urinari
normetanephrin
creatinin
ratio
may
best
test
discrimin
pheo
hypercortisol
hc
knowledg
plasma
catecholamin
metanephrin
dog
scarc
comparison
urinari
plasma
paramet
perform
object
studi
measur
urinari
plasma
catecholamin
metanephrin
dog
pheo
hc
healthi
dog
determin
test
least
overlap
group
six
dog
pheo
dog
hc
ath
pdh
healthi
dog
includ
urin
sampl
collect
hcl
contain
tube
ensur
ph
blood
sampl
collect
ice
centrifug
immedi
snap
frozen
liquid
nitrogen
sampl
store
urinari
epinephrin
uepi
norepinephrin
unorepi
metanephrin
umeta
normetanephrin
unormeta
plasma
epinephrin
pepi
norepinephrin
pnorepi
free
total
metanephrin
pfmeta
ptmeta
free
total
normetanephrin
pfnormeta
ptmeta
analys
hplc
urinari
catecholamin
metanephrin
express
ratio
urin
creatinin
concentr
data
analys
nonparametr
test
p
similar
previou
find
uepi
unorepi
umeta
unormeta
significantli
higher
dog
pheo
unorepi
unormeta
significantli
higher
dog
hc
compar
healthi
dog
comparison
dog
hc
dog
pheo
reveal
significantli
higher
umeta
unormeta
latter
group
unormeta
paramet
overlapin
dog
pheo
pnorepi
pfmeta
ptmeta
pfnormeta
ptnormeta
significantli
higher
dog
hc
pnorepi
pfnormeta
ptnormeta
significantli
higher
healthi
dog
comparison
dog
hc
dog
pheo
show
signific
higher
pfmeta
ptmeta
pfnormeta
ptnormeta
pheo
group
overlap
present
paramet
least
pfnormeta
ptnormetaaccord
preliminari
result
unormeta
pfnormeta
ptnormeta
valuabl
paramet
diagnosi
pheo
far
unormeta
perform
better
plasma
paramet
chronic
kidney
diseas
ckd
common
geriatr
cat
hypoxia
might
contribut
ckd
progress
vascular
endotheli
growth
factor
vegf
marker
hypoxia
aim
studi
evalu
urinari
vegf
prognost
marker
cat
ckd
compar
establish
progress
factor
proteinuria
hyperphosphataemia
cat
recruit
geriatr
clinic
held
two
first
opinion
london
practic
diagnosi
ckd
base
concurr
find
plasma
creatinin
usg
persist
azotaemia
least
week
vegf
measur
urin
sampl
taken
cat
diagnosi
ckd
index
creatinin
give
vegf
creatinin
ratio
uvc
surviv
compar
among
low
medium
high
categori
uvc
use
logrank
test
multivari
binari
logist
regress
use
assess
whether
uvc
associ
increas
plasma
creatinin
concentr
least
within
year
diagnosi
cat
demonstr
progress
follow
exclud
studi
case
develop
hyperthyroid
receiv
ace
inhibitor
gross
haematuria
urinari
tract
infect
nephrot
syndrom
evid
bladder
neoplasia
also
exclud
surviv
data
present
median
confid
interv
descript
data
present
median
th
th
percentil
signific
set
p
cat
low
uvc
surviv
day
medium
high
uvc
surviv
day
day
respect
differ
surviv
time
cat
low
medium
valu
uvc
cat
low
p
medium
uvc
significantli
longer
surviv
cat
high
uvc
plasma
creatinin
concentr
increas
cat
progress
cat
stabl
renal
function
year
follow
diagnosi
uvc
also
associ
progress
azotaemia
independ
upc
plasma
phosphat
concentr
progress
group
uvc
lgg
stabl
group
uvc
lgg
high
uvc
indic
renal
hypoxia
result
studi
support
hypothesi
hypoxia
associ
progress
cat
ckd
howev
studi
evalu
renal
hypoxia
directli
would
requir
verifi
term
triaditi
use
describ
concurr
inflamm
liver
pancrea
small
intestin
although
occasion
two
organ
may
particip
aim
studi
investig
frequenc
coexist
differ
combin
cholang
pancreat
andor
inflammatori
bowel
diseas
cat
describ
clinic
clinicopatholog
histopatholog
findingsiniti
cat
includ
studi
thirtynin
cat
suspicion
triaditi
base
clinic
sign
depress
anorexia
polyphagia
vomit
diarrhea
andor
weight
loss
cat
clinic
healthi
consid
control
cat
present
underw
cbc
biochemistri
profil
serum
total
spec
fpl
ftli
blood
examin
cat
diagnos
intestin
parasit
infecti
diseas
neoplasia
andor
hyperthyroid
exclud
studi
biopsi
liver
pancrea
small
intestin
duodenum
jejunum
ileum
collect
sick
cat
laparotomi
part
diagnost
investig
biopsi
healthi
cat
collect
laparotomi
ovariohysterectomi
owner
sign
consent
form
studi
protocol
approv
univers
state
ethic
committeeof
sick
cat
suspicion
triaditi
exclud
neoplasia
condit
clinic
healthi
cat
histopatholog
evid
inflamm
liver
pancrea
andor
intestin
eventu
group
togeth
sick
cat
collect
histopatholog
evalu
biopsi
reveal
cat
clinic
sign
without
inflammatori
lesion
least
one
organ
cat
histopatholog
evid
ibd
cholang
pancreat
thirteen
cat
ibd
symptomat
six
cat
cholang
symptomat
one
pancreat
symptomat
sixteen
cat
concurr
ibd
cholang
symptomat
ibd
combin
pancreat
symptomat
ibd
cholang
pancreat
symptomat
common
biochem
find
increas
activ
alt
alp
increas
total
bilirubin
ftli
spec
fpl
concentrationsth
result
studi
indic
differ
combin
concurr
inflamm
liver
pancrea
intestin
exist
cat
also
appear
condit
may
subclin
mani
case
sever
potenti
pathogen
found
felin
faec
rang
signific
incident
pathogen
treatment
recommend
base
accompani
clinic
sign
real
time
pcr
enabl
rapid
screen
small
quantiti
faec
potenti
pathogen
high
sensit
specif
cocarriag
felin
faecal
pathogen
may
reflect
symbiot
relationship
relat
pathogenesi
case
identif
common
cocarriag
pattern
may
influenc
treatment
decis
prognosi
primari
object
studi
identifi
cocarriag
select
felin
faecal
pathogen
secondari
object
evalu
preval
individu
pathogen
felin
faec
associ
pedigre
statu
histori
diarrhoea
result
commerci
felin
diarrhoea
realpcr
tm
panel
idexx
refer
laboratori
uk
june
januari
evalu
real
time
pcr
perform
tritrichomona
foetu
giardiaspp
cryptosporidiumspp
toxoplasmagondii
salmonellaspp
clostridium
perfringen
enterotoxin
gene
felin
coronaviru
felin
panleukopenia
viru
addit
data
record
avail
includ
age
gender
breed
histori
diarrhoea
weak
borderlin
posit
result
pool
faecal
sampl
exclud
associ
carriag
pair
pathogen
evalu
chisquar
test
statist
signific
set
p
pcr
panel
evalu
preval
faecal
pathogen
tritrichomona
foetu
giardia
cryptosporidium
toxoplasma
gondii
salmonella
clostridium
perfringen
felin
coronaviru
felin
panleukopenia
viru
salmonella
faecal
pathogen
significantli
associ
histori
diarrhoea
faecal
sampl
pedigre
cat
significantli
like
dsh
posit
tritrichomona
foetu
giardia
clostridium
perfringen
felin
coronavirussignific
cocarriag
identifi
felin
coronaviru
pathogen
except
salmonella
signific
cocarriag
tritrichomona
foetu
clostridium
perfringen
giardia
also
giardia
panleukopenia
viru
cryptosporidium
clostridium
perfringen
final
signific
cocarriag
cryptosporidium
clostridium
perfringen
panleukopenia
viru
cryptosporidium
toxoplasma
gondii
salmonellain
conclus
moder
high
preval
felin
faecal
pathogen
test
except
toxoplasma
gondii
salmonella
posit
pcr
result
like
pedigre
cat
salmonella
associ
histori
diarrhoea
signific
cocarriag
faecal
pathogen
common
possibl
reflect
common
environment
risk
factor
share
pathogenesi
symbiot
relationship
mycoplasma
spp
identifi
caus
pathogen
felin
lower
airway
diseas
thought
colon
lower
airway
clinic
healthi
catsto
challeng
hypothesi
domest
shorthair
cat
age
year
median
year
without
sign
respiratori
diseas
hous
shelter
underw
transor
lower
airway
wash
steril
salin
gener
anaesthesia
retriev
bronchalveolar
lavag
fluid
balf
subject
microbiolog
cytolog
analysisdur
preanaesthet
clinic
examin
minor
alter
discov
tartar
conjunct
flea
infest
dirti
auditori
canal
cat
one
anim
show
dandruff
corneal
ulcer
heart
murmur
anim
posit
mycoplasma
spp
examin
cat
mycoplasma
feli
balf
light
growth
moder
growth
heavi
growth
anim
ureaplasma
felinumcati
light
growth
moder
growth
case
mycoplasma
gatea
light
growth
moder
growth
heavi
growth
cat
mycoplasma
feliminutum
light
growth
anim
use
aerob
bacteri
cultur
pasteurella
multocida
ahaemolyt
streptococci
haemolyt
e
coli
acinetobact
iwoffii
detect
sampl
yield
neg
resultsmedian
balftot
nucleat
cell
count
rang
median
mononucl
cell
percentag
median
neutrophil
fraction
median
eosinophil
proport
sampl
neutrophildomin
indic
purul
inflamm
specimen
posit
mycoplasma
feli
light
growth
heavi
growth
one
show
moder
growth
pasteurella
multocida
like
anim
includ
studi
correspond
cat
remain
clinic
healthi
followup
periodbalfsampl
show
neither
cytolog
microbiolog
sign
indic
upper
airway
contaminationin
contrast
earlier
studi
conclud
least
cat
hous
shelter
subject
high
infect
pressur
addit
bacteria
like
pasteurella
spp
streptococcu
spp
e
coli
mycoplasma
spp
occur
felin
lower
airway
without
caus
respiratori
sign
inflammasom
intracellular
multiprotein
complex
coordin
matur
interleukin
il
respons
pathogen
metabol
danger
signal
cytokin
vital
mainten
intestin
homeostasi
link
chronic
intestin
inflamm
human
produc
inact
proform
undergo
subsequ
matur
cleavag
activ
form
caspas
casp
turn
activ
inflammasom
complex
best
character
inflammasom
subtyp
human
inflammatori
bowel
diseas
ibd
seem
crucial
regul
intestin
homeostasi
defect
signal
suggest
contribut
ibd
addit
upregul
mrna
protein
level
human
ibd
far
studi
investig
role
inflammasom
respect
downstream
cytokin
canin
ibd
thu
goal
current
studi
investig
express
inflammasom
compon
duoden
tissu
dog
ibd
compar
healthi
control
rna
extract
endoscop
biopsi
ibd
group
n
control
group
n
reversetranscriptas
quantit
pcr
perform
sybrgreenbas
assay
use
specif
primer
follow
canin
gene
dilut
plasmid
control
gene
use
assess
assay
effici
rel
quantif
gene
express
perform
use
three
refer
gene
gapdh
sdha
tbp
comparison
group
perform
use
mann
whitney
u
test
graph
pad
prism
signific
set
p
eight
sampl
ibd
control
exclud
due
poor
cdna
qualiti
inadequ
express
refer
gene
compar
remain
sampl
group
p
p
express
significantli
lower
ibd
dog
control
contrast
p
p
express
differ
groupsdownregul
could
part
neg
feedback
loop
proinflammatori
environ
ibd
altern
could
repres
gener
disturb
intestin
homeostasi
failur
upregul
dangersign
pathway
inflamm
final
conclus
might
difficult
draw
without
match
protein
data
assess
mrna
level
give
insight
ratio
procytokin
activ
cytokin
thu
investig
protein
content
canin
ibd
tissu
warrant
futur
trefoil
factor
famili
tff
compris
group
small
peptid
produc
goblet
cell
crucial
epitheli
restitut
mainten
tight
junction
function
gut
human
inflammatori
bowel
diseas
ibd
tff
express
upregul
thought
repres
unspecif
repair
mechan
howev
tff
also
shown
involv
local
control
diseas
rodent
model
human
far
studi
investig
tff
express
canin
intestin
thu
goal
studi
assess
tff
express
gastrointestin
tissu
dog
ibd
healthi
dog
rna
extract
endoscop
duoden
ibd
n
healthi
control
n
colon
biopsi
ibd
n
control
n
cdna
gener
quantit
reversetranscript
pcr
perform
canin
sybrgreenbas
assay
dilut
plasmid
control
gene
use
assess
assay
effici
rel
quantif
gene
express
perform
use
three
refer
gene
gapdh
sdha
tbp
statist
analysi
signific
set
p
overal
express
significantli
differ
across
group
kruskal
walli
p
control
dog
express
higher
colon
duodenum
mann
whitney
p
compar
ibd
case
control
duoden
significantli
upregul
mann
whitney
p
express
differ
across
group
kruskal
walli
p
howev
separ
analysi
intestin
locat
show
signific
downregul
colon
ibd
dog
compar
control
ttest
p
studi
demonstr
evid
dysregul
tff
gene
express
canin
ibd
lack
could
contribut
defect
epitheli
barrier
function
caus
leaki
tight
junction
increas
intestin
permeabl
could
lead
increas
antigen
load
microb
food
antigen
could
perpetu
faulti
immun
recognit
microbeassoci
molecular
pattern
thu
lead
increas
intestin
inflamm
upregul
colon
could
turn
signifi
compensatori
repairmechan
inflamm
investig
tff
gene
protein
express
warrant
canin
ibd
canin
inflammatori
bowel
diseas
ibd
thought
partial
caus
aberr
immun
respons
toward
intestin
microbiom
human
mice
administr
probiot
allevi
ibd
sever
andor
prevent
relaps
induct
toler
microenviron
aim
studi
investig
effect
probiot
enterococcu
faecium
ncimb
ef
gene
express
protein
product
canin
duoden
biopsi
sampl
healthi
beagl
ibd
dog
cultur
exvivo
ef
cfuml
steril
nutrient
broth
pb
neg
control
hour
rna
extract
biopsi
reversetranscriptas
quantit
pcr
perform
sybrgreenbas
assay
use
specif
primer
follow
canin
gene
tgfb
ifnc
tnfa
use
dilut
plasmid
control
gene
assess
assay
effici
rel
quantif
gene
express
perform
use
three
refer
gene
gapdh
sdha
tbp
protein
content
ifnc
tnfa
measur
cultur
supernat
use
commerci
avail
caninespecif
elisa
linear
mix
model
genewith
diseas
group
treatment
set
fix
paramet
chosen
statist
analysi
use
spss
softwar
signific
set
p
signific
interact
diseas
group
treatment
observ
gene
express
significantli
increas
ibd
dog
compar
healthi
dog
p
unstimul
sampl
signific
differ
independ
diseas
group
depend
treatment
ef
express
follow
gene
reduc
ef
treatment
tlr
p
p
p
tgfb
p
ifnc
p
tnfa
p
signific
amount
ifnc
tnfa
protein
detect
cultur
supernatantsthi
first
studi
demonstr
profound
effect
ef
treatment
gene
express
ex
vivo
cultur
canin
duoden
biopsi
downregul
sever
gene
innat
immun
receptor
proinflammatori
cytokin
observ
signific
effect
suppress
tnfa
express
effect
seen
healthi
ibd
dog
whether
translat
benefici
effect
clinic
situat
need
investig
recent
molecular
studi
reveal
highli
complex
bacteri
microbiota
intestin
cat
mount
evid
microb
play
import
role
pathogenesi
chronic
enteropathi
composit
chang
intestin
bacteri
ecosystem
associ
chronic
intestin
inflamm
human
dog
aim
studi
character
bacteri
microbiota
cat
chronic
enteropathiesfec
sampl
obtain
healthi
cat
cat
histolog
confirm
chronic
enteropathi
bacteri
composit
analyz
massiv
parallel
rrna
gene
yield
sequenc
tag
select
quantit
pcr
assay
differ
microbi
commun
structur
healthi
diseas
cat
assess
phylogenet
unifrac
distanc
method
follow
analysi
similar
anosim
distanc
matrix
differ
bacteri
group
diseas
group
analyz
use
mannwhitney
u
test
result
pvalu
correct
multipl
comparison
use
benjamini
hochberg
fals
discoveri
rate
adjust
p
consid
statist
significanceth
unifrac
distanc
metric
indic
signific
cluster
accord
diseas
statu
howev
rel
proport
sequenc
belong
bacteroid
spp
significantli
decreas
cat
chronic
enteropathi
compar
healthi
cat
employ
qpcr
assay
confirm
sequenc
result
also
show
signific
decreas
proport
bacteroid
spp
diseas
cat
addit
qpcr
reveal
also
signific
decreas
turicibact
spp
cat
chronic
enteropathi
compar
healthi
cat
signific
differ
divers
indic
observ
healthi
diseas
catsin
conclus
use
molecular
approach
reveal
signific
reduct
bacteroid
turicibact
spp
cat
chronic
enteropathi
futur
studi
necessari
evalu
microbi
chang
correl
function
chang
intestin
microbiota
campylobact
spp
repres
common
caus
gastroenter
human
c
jejuni
c
coli
consid
respons
major
clinic
case
mani
human
diagnost
laboratori
use
prospect
campylobact
micropl
assay
eia
sole
screen
test
detect
c
jejuni
c
coli
techniqu
easier
faster
cheaper
campylobact
spp
cultur
c
upsaliensi
caus
diarrhoeal
ill
similar
caus
c
jejuni
human
method
routin
use
c
jejuni
c
coli
detect
includ
eia
optimis
evalu
detect
campylobact
speci
c
upsaliensi
c
helveticu
commonli
isol
dog
cat
c
jejuni
c
coli
studi
campylobact
spp
pet
potenti
zoonot
pathogen
pet
remain
uncertain
signific
c
upsaliensi
c
helveticu
infect
may
underestim
human
medicin
due
detect
method
appliedth
aim
pilot
studi
assess
eia
detect
c
upsaliensi
c
helveticu
isol
differ
pet
spike
human
clinic
sampl
addit
abil
eia
detect
campylobact
spp
dog
cat
faec
assess
ten
clinic
human
faecal
sampl
two
healthi
dog
cat
faec
confirm
neg
eia
test
rang
cultur
method
exclud
presenc
campylobact
spp
dilut
eight
c
upsaliensi
five
c
helveticu
cultur
one
c
jejuni
c
coli
cultur
pcr
confirm
ad
aliquot
faecal
sampl
obtain
rang
viabl
bacteria
cfuml
eia
perform
follow
manufactur
instruct
duplic
fifti
sampl
test
posit
eia
variou
dilut
c
upsaliensi
c
helveticu
c
jejuni
c
coli
detect
limit
vari
isol
lower
wateri
semisolid
faecesin
conclus
eia
detect
c
upsaliensi
c
helveticu
spike
faec
human
clinic
case
campylobact
spp
test
healthi
pet
eia
use
sole
detect
method
cultur
method
select
follow
posit
eia
result
enabl
detect
wide
rang
campylobact
spp
addit
eia
may
use
test
pet
rule
campylobact
spp
infect
epidemiolog
investig
highresolut
manometri
hrm
gold
standard
evalu
function
esophag
motil
disord
human
inform
noninvas
techniqu
avail
dog
aim
studi
evalu
feasibl
hrm
dog
gener
first
normal
valu
examin
influenc
standard
sedat
esophag
pressur
profileth
studi
popul
consist
healthi
adult
beagl
dog
mean
bw
kg
studi
protocol
approv
local
ethic
committe
hrm
perform
sit
posit
fast
lidocain
jelli
use
lubric
solidst
cathet
sierra
scientif
mm
diamet
circumferenti
pressur
sensor
space
cm
apart
insert
intranas
measur
start
minut
adapt
time
realtim
pressur
imag
cathet
intub
enabl
accur
placement
manometr
protocol
includ
water
can
food
bolu
swallow
procedur
repeat
minut
standard
im
sedat
acepromazin
buprenorphin
data
analys
use
manoview
softwar
result
awak
vs
sedat
compar
use
wilcoxon
test
statist
signific
set
p
could
success
perform
dog
reason
unsuccess
examin
defenc
reaction
inabl
pass
ventral
meatu
revers
sneez
upper
esophag
sphincter
ue
characteris
compris
baselin
pressur
residu
pressur
nadir
ue
relax
swallow
relax
durat
tubular
esophag
function
characteris
compris
peristalt
contractil
integr
pci
amplitud
x
durat
x
length
contract
wave
bolu
transit
time
btt
lower
esophag
sphincter
le
characteris
compris
baselin
pressur
residu
pressur
lowest
continu
second
mean
le
pressur
rel
intragastr
pressur
swallow
induc
relax
median
valu
waterfood
bolu
swallow
awak
sedat
dog
calcul
ue
baselin
pressur
mmhg
residu
pressur
mmhg
relax
durat
ms
ii
tubular
esophagu
function
pci
mmhgcm
btt
ms
iii
le
baselin
pressur
mmhg
residu
pressur
mmhg
signific
differ
found
ue
relax
durat
water
btt
food
bolu
conclus
hrm
feasibl
techniqu
evalu
esophag
function
dog
patient
requir
sedat
still
examin
howev
point
clear
sedat
would
affect
assess
motil
disord
dysphag
dog
human
ambulatori
intraesophag
phmonitor
util
bravo
capsul
standard
test
establish
patholog
gastroesophag
reflux
ger
techniqu
provid
inform
esophag
acid
exposur
also
abl
assess
symptom
associ
ger
dog
ger
poorli
understood
clear
ger
actual
repres
clinic
relev
problemth
goal
studi
examin
canin
esophag
ph
milieu
health
examin
esophag
ph
dog
present
sign
commonli
attribut
ger
veterinari
literaturethirteen
clientown
dog
cod
variou
breed
median
bw
median
age
includ
clinic
sign
ultim
lead
phmonitor
compris
lipsmack
repeat
swallow
motion
chronic
vomit
cough
retch
regurgit
sudden
discomfort
excess
surfacelick
ptyalism
presum
postprandi
pain
refus
eat
despit
interest
histori
esophag
foreign
bodi
halitosi
dog
show
median
sign
dog
addit
diarrhea
six
healthi
beagl
median
bw
median
age
unremark
gastroduoden
evalu
serv
control
c
prior
antacid
prokinet
treatment
allow
capsul
endoscop
place
cm
lower
esophag
sphincter
ph
data
transmit
everi
receiv
attach
dog
collar
owner
instruct
press
individu
predefin
symptombutton
receiv
whenev
indic
chang
daili
routin
data
analys
use
rapidph
softwar
reflux
defin
singl
phmeasur
result
group
compar
use
nonparametr
teststh
median
phmonitor
period
codc
follow
paramet
median
rang
codc
evalu
number
reflux
number
longest
reflux
durat
longest
reflux
min
fraction
time
ph
differ
group
median
number
button
push
dog
refluxposit
push
push
mild
distal
esophag
note
dog
final
diagnos
foodrespons
ibd
steroidrespons
ibd
allerg
skin
diseas
chronic
laryngotracheobronch
muscular
dystrophi
dog
present
histor
clinic
sign
interpret
ger
may
relev
reflux
episod
consid
normal
valu
establish
human
none
dog
would
classifi
abnorm
aim
present
studi
evalu
chang
biochem
ultrasonograph
us
paramet
group
dog
natur
occur
acut
pancreat
ap
therapeut
followupdog
clinic
sign
abdomin
us
find
suggest
ap
associ
increas
serum
canin
pancreat
lipas
cpl
activ
includ
studi
dog
serum
concentr
creactiv
protein
crp
amylas
lipas
also
measur
sever
index
establish
semiquantit
evalu
sever
clinic
us
find
particular
clinic
score
follow
clinic
paramet
given
presenc
frequenc
vomit
appetit
gener
condit
us
score
assign
per
follow
paramet
pancrea
echogen
volum
echotextur
echogen
mesenteri
gastrointestin
tract
biliari
duct
lymph
node
abdomin
effus
total
score
dog
treat
fluid
therapi
ampicillinsulbactam
iv
buprenorphin
need
maropit
sc
two
sever
score
serum
crp
amylas
lipas
concentr
measur
diagnosi
day
discharg
td
week
discharg
nine
clientown
dog
includ
median
rang
age
year
year
median
rang
clinic
us
score
respect
respect
signific
posit
correl
found
clinic
us
score
p
median
rang
serum
concentr
crp
mgdl
amylas
ul
lipas
ul
respect
respect
admiss
serum
crp
amylas
lipas
level
increas
dog
respect
increas
dog
respect
serum
crp
amylas
lipas
concentr
decreas
follow
significantli
p
lower
compar
suggest
us
find
crp
amylas
concentr
correl
recoveri
ap
studi
warrant
evalu
use
paramet
followup
ap
wider
popul
dog
enzym
replac
therapi
mainstay
therapi
exocrin
pancreat
insuffici
epi
dog
entericco
prepar
develop
protect
enzym
degrad
stomach
efficaci
critic
evalu
hypothesi
current
studi
enter
coat
would
effect
efficaci
pancreat
enzym
supplement
dog
epithirtyeight
clientown
dog
natur
occur
epi
includ
multicentr
blind
randomis
control
trial
dog
receiv
either
entericco
enzym
prepar
test
group
ident
prepar
without
enter
coat
control
group
period
daysther
signific
differ
baselin
characterist
test
control
treatment
group
bodi
weight
bodi
condit
score
increas
group
trial
p
magnitud
increas
greater
test
treatment
compar
control
treatment
p
day
mean
bodi
weight
increas
confid
interv
treatment
group
confid
interv
control
group
dose
enzym
use
increas
time
p
signific
treatment
group
differ
time
point
clinic
diseas
sever
score
decreas
significantli
time
group
signific
differ
note
group
signific
advers
effect
report
either
treatment
durat
trialad
enter
coat
pancreat
enzym
supplement
convey
therapeut
advantag
treat
dog
epi
liver
injuri
caus
toxin
inhibit
hepatocyt
replic
prolif
potenti
hepatocyt
exhaust
due
chronic
condit
diseas
hepatocytedepend
liver
regener
strongli
impair
situat
anoth
cell
compart
activ
regener
liver
hepat
progenitor
cell
compart
bipot
hepat
progenitor
cell
hpc
differenti
hepatocyt
cholangiocyt
hpc
activ
sever
liver
diseas
may
well
cell
origin
subtyp
hepatocellular
carcinoma
hcc
polycomb
group
protein
involv
murin
hpc
activ
prognost
relev
hcc
therefor
investig
express
canin
liver
diseas
includ
hcc
function
consequ
deregul
express
includ
reveal
feasibl
liver
regen
medicineimmunohistochemistri
ihc
laser
microdissect
follow
gene
express
analysi
use
investig
express
activ
hpc
hcc
elucid
role
hpc
vitro
gene
silenc
experi
follow
gene
express
analysi
western
blot
analysi
prolifer
assay
eduincorpor
perform
human
hpclike
celllin
hepargihc
gene
express
show
strong
nuclear
express
activ
hpc
canin
liver
diseas
keratin
marker
hpc
cholangiocyt
high
express
associ
poor
prognosi
hcc
stain
intens
highli
malign
hepatocellular
carcinoma
posit
keratin
compar
keratin
neg
hcc
vitro
studi
reveal
significantli
reduc
hpc
prolifer
suggest
role
differenti
gene
express
hpcsthese
result
indic
express
activ
hpc
liver
diseas
test
need
prolifer
hpc
vitro
potenti
involv
hpc
differenti
express
hcc
suggest
role
tumour
develop
potenti
due
persist
activ
hpc
therefor
enhanc
activ
lead
progenitor
cell
benefici
like
also
aggress
hcc
hpcsignatur
hepat
progenitor
cell
hpc
bipotenti
form
cholangiocyt
hepatocyt
result
express
marker
cell
type
variou
marker
use
select
hpc
yet
specif
cell
marker
transmembran
glycoprotein
identifi
organ
stem
cell
marker
cancer
stem
cell
marker
use
select
hpc
rodent
human
canin
hpc
shown
gene
express
studi
aim
assess
select
could
enrich
canin
hpcsa
wedg
liver
healthi
dog
euthanas
behaviour
reason
digest
collagenas
perfus
hepatocyt
remov
pellet
min
remain
nonparenchym
cell
npc
pellet
min
magnet
assist
cell
sort
mac
cell
posit
neg
perform
accord
manufactur
instruct
posit
neg
npc
cultur
bovin
type
collagenco
plate
hepatocyt
cultur
media
lonza
cell
morpholog
monitor
rna
extract
cdna
produc
cell
pellet
immedi
separ
also
week
cultur
rel
gene
express
cholangiocyt
marker
keratin
hepatocyt
marker
albumin
perform
use
refer
genesth
posit
fraction
npc
morpholog
posit
cell
form
coloni
cell
small
cytoplasm
nucleu
ratio
transform
hepatoblast
appear
neg
cell
produc
fibroblast
cell
compar
neg
cell
initi
posit
cell
show
increas
increas
cholangiocyt
marker
well
modest
increas
hepatocyt
marker
albumin
modest
decreas
week
cultur
posit
cell
express
albumin
compar
neg
cultur
express
reduc
increas
cultureth
posit
fraction
express
cholangiocyt
hepatocyt
marker
compar
neg
cell
initi
sort
week
cultur
posit
cell
form
hepatocytelik
coloni
well
continu
greater
hepatocyt
cholangiocyt
gene
express
express
decreas
consist
differentiationa
larg
percentag
npc
posit
sort
also
label
haematopoiet
mesenchym
stem
cell
therefor
subsequ
use
fac
marker
may
enrich
specif
hpc
compart
hepat
neoplasm
dog
classifi
hepatocellular
adenoma
carcinoma
cholangiocellular
adenoma
carcinoma
mix
hepatoand
cholangiocellular
carcinoma
hepat
carcinoid
past
decad
mani
advanc
made
character
primari
liver
tumour
man
knowledg
result
propos
new
morpholog
immunohistochem
classif
primari
liver
tumour
facilit
diagnosi
categor
tumour
includ
aggress
prognosi
purpos
studi
investig
presenc
rel
incid
variou
morpholog
type
primari
hepat
neoplasm
dog
determin
whether
new
human
classif
also
appli
canin
hepat
neoplasm
studi
canin
primari
liver
tumour
examin
histolog
classifi
use
sever
immunohistochem
marker
includ
keratin
k
hepat
progenitor
stem
cellbil
duct
epithelium
marker
hepatocyt
marker
ema
mucin
produc
biliari
epithelium
marker
pcea
canalicular
ductular
bile
duct
epithelium
marker
nse
chromogranina
neuroendocrin
marker
addit
tumour
grade
accord
cellular
nuclear
pleiomorph
mitot
index
stage
respect
absenc
presenc
invas
growth
intrahepat
andor
distant
metastas
primari
liver
tumour
hepatocellular
origin
hepatocellular
tumour
could
subdivid
hepatocellular
tumour
posit
tumour
posit
hepatocellular
tumour
posit
histolog
poorli
differenti
often
reveal
lymphat
vascular
invas
portal
tract
show
intrahepat
andor
distant
metastasi
contrast
hepatocellular
tumour
posit
almost
alway
well
differenti
well
demarc
evid
vascular
invas
intrahepat
andor
distant
metastasi
eight
tumour
cholangiocellular
origin
cholangiocellular
tumour
poorli
differenti
grade
show
intrahepat
andor
distant
metastas
third
group
primari
liver
tumour
neuroendocrin
characterist
consist
five
tumour
classifi
carcinoid
histolog
poorli
differenti
intrahepat
andor
distant
metastas
conclus
morpholog
type
primari
hepat
neoplasm
dog
includ
aggress
prognosi
highli
compar
situat
man
find
indic
new
human
classif
primari
hepat
neoplasm
applic
dog
doberman
hepat
dh
rare
inflammatori
liver
diseas
character
femal
preponder
elev
serum
transaminas
activ
increas
hepat
copper
content
immun
system
involv
suggest
presenc
lymphocyt
infiltr
femal
predisposit
abnorm
express
major
histocompat
complex
mhc
class
ii
antigen
hepatocyt
associ
homozygos
mhc
ii
risk
allel
dog
leukocyt
antigen
system
genotypew
investig
possibl
autoantibodi
involv
dh
serum
sampl
subclin
clinic
dh
patient
clinic
healthi
control
doberman
includ
elisa
assay
detect
igg
autoantibodi
histon
aha
cutoff
valu
posit
antihiston
elisa
determin
use
mean
absorb
sd
sampl
healthi
control
valu
subclin
dh
case
mean
confid
interv
ci
clinic
dh
case
mean
ci
significantli
higher
valu
control
mean
ci
p
seroposit
note
control
groupautoantibodi
serolog
hallmark
autoimmun
diseas
normal
immun
system
extraordinari
capac
prevent
selfantigen
stimul
inflammatori
reaction
presenc
autoantibodi
therefor
consequ
breakdown
failur
bcell
toler
toward
correspond
autoantigen
sinc
appear
aha
indic
possibl
presenc
autoimmun
result
support
assumpt
dh
autoimmun
diseas
man
best
friend
cani
lupu
familiari
ideal
model
organ
broad
varieti
natur
occur
diseas
dog
breed
popul
structur
suit
genet
studi
complex
disord
haploblock
within
dog
breed
extend
time
longer
distanc
human
popul
relat
dog
breed
often
share
phenotyp
caus
mutat
allow
finemap
valid
inbreed
bottleneck
dog
popul
led
increas
incid
genet
diseas
remain
incident
panmict
human
populationsextrahepat
portosystem
shunt
ehpss
larg
abnorm
venou
blood
vessel
connect
portal
vein
major
system
vein
result
almost
complet
divers
portal
blood
past
liver
lead
lack
liver
function
liver
growth
hepat
encephalopathi
due
brain
neurotransmitt
dysfunct
report
human
case
wherea
diseas
widespread
dog
shunt
frequent
diagnos
purebr
dog
crossbr
dog
inherit
complex
without
sex
effecta
genom
wide
associ
studi
snp
peform
cairn
terrier
case
control
breed
qualiti
control
case
control
analyz
snp
allel
associ
calcul
plink
gramma
genabel
packag
use
correct
genet
kinship
sever
chromosom
region
detect
close
signific
associ
overlap
two
analysi
method
found
three
genom
region
cover
mb
finemap
conduct
analyz
snp
larger
group
cairn
terrier
case
control
breed
finemap
result
two
genom
region
cover
kb
associ
signific
pvalu
comparison
haplotyp
case
differ
breed
confirm
associ
signal
region
interest
analyz
ng
case
control
histor
doxycyclin
first
line
drug
treatment
canin
monocyt
ehrlichiosi
cme
studi
shown
dog
may
remain
carrier
despit
doxycyxlin
treatment
therefor
investig
antiehrlichi
agent
may
warrant
rifampin
suggest
promis
altern
treatment
cme
though
efficaci
clear
infect
thoroughli
evalu
purpos
studi
assess
efficaci
rifampin
achiev
clinicopatholog
recoveri
clear
ehrlichi
infect
blood
tissu
dog
experimentallyinduc
acut
cme
purposebr
beagl
dog
includ
studi
dog
acut
experiment
cme
treat
rifampin
mgkg
sid
po
week
infect
dog
receiv
rifampin
infect
control
two
dog
serv
uninfect
control
fourteen
day
complet
rifampin
treatment
dexamethazon
mgkg
iv
given
rifampintr
dog
clinic
score
platelet
count
anti
cani
immunofluorsec
antibodi
titer
ifa
polymeras
chain
reaction
pcr
detect
e
canisspecif
deoxyribonucl
acid
blood
bone
marrow
spleen
aspir
evalu
treat
untreat
infect
dog
day
postinocul
pi
start
rifampin
day
pi
end
rifampin
day
pi
end
posttreat
monitor
day
pi
infect
dog
becam
clinic
ill
thrombocytopen
seroconvert
becam
pcrposit
least
one
tissu
median
clinic
score
ifa
titer
differ
treat
untreat
dog
three
time
point
platelet
count
significantli
higher
treat
compar
untreat
infect
dog
day
pi
versu
day
pi
versu
twosampl
wilcoxon
ranksum
mannwhitney
test
day
pi
treat
untreat
infect
dog
pcrposit
day
pi
treat
untreat
infect
dog
remain
pcr
posit
least
one
tissu
test
administ
studi
rifampin
hasten
hematolog
recoveri
infect
dog
inconsist
clear
experimentallyinduc
acut
e
cani
infect
acut
phase
protein
app
consid
one
hallmark
inflammatori
respons
among
major
function
app
seem
modul
innat
immun
system
effici
cat
serum
amyloid
saa
agp
two
major
posit
app
increas
inflamm
rise
presum
secondari
variou
cytokin
involv
innat
inflammatori
responserecombin
felin
interferonx
rfeifnx
immunemodul
drug
commonli
use
cat
natur
infect
retrovirus
name
felin
immunodefici
viru
fiv
felin
leukemia
viru
felv
sever
studi
perform
clarifi
clinic
benefit
rfeifnx
therapi
natur
infect
fiv
andor
felv
cat
group
previous
describ
creactiv
protein
crp
increas
natur
retroviralinfect
cat
rfeifnx
therapi
howev
role
app
saa
agp
crp
innat
immunerespons
remain
unknownth
aim
studi
evalu
saa
agp
crp
serum
level
natur
retroviralinfect
cat
rfeifnx
therapysixteen
natur
retrovir
infect
cat
fiv
felv
coinfect
fivfelv
stray
cat
hous
lisbonanim
rescu
shelter
submit
rfeifnx
therapi
licens
protocol
use
cours
sc
administ
daili
day
begin
day
blood
sampl
collect
saa
agp
crp
quantif
treatment
saa
quantifi
elisa
phase
saa
tridelta
agp
determin
singl
radial
immunodifus
agp
tridelta
felin
crp
quantifi
elisa
kamiya
biomed
compani
app
serum
level
compar
rfeifnx
therapi
statist
signific
increas
saa
agp
respect
friedman
test
observ
comparison
find
corrobor
signific
increas
crp
serum
level
previous
describ
p
test
app
test
behav
similarli
show
evid
increas
serum
valu
rfeifnx
therapi
result
suggest
possibl
immun
modul
effect
induc
rfeifnx
seem
maxim
effici
innat
immun
respons
studi
correl
find
cytokin
profil
extend
knowledg
effici
rfeifnx
therapi
natur
retrovir
infect
cat
canin
theileriosi
tickborn
diseas
caus
protozoan
parasit
genera
theileria
associ
anaemia
andor
thrombocytopaenia
clinic
manifest
diseas
dog
poorli
describ
diseas
emerg
import
diagnos
sever
dog
emphas
need
elucid
specif
pathogen
speci
character
clinic
manifest
diseasethi
retrospect
studi
describ
clinic
characterist
diagnost
test
treatment
outcom
six
client
own
clinic
ill
dog
diagnos
canin
theileriosi
onderstepoort
veterinari
academ
hospit
south
africa
canin
theileriosi
diagnos
polymeras
chain
reaction
pcr
wholeblood
follow
revers
line
blot
rlb
hybrid
assay
tickborn
diseas
neoplast
condit
excludedth
common
clinic
find
pale
mucou
membran
dog
lethargi
dog
oral
bleed
dog
dog
thrombocytopaenia
median
x
l
rang
dog
anaemia
median
haematocrit
rang
anaemia
regen
dog
nonregen
dog
one
dog
posit
salin
autoagglutin
test
bone
marrow
cytolog
core
biopsi
perform
two
dog
sever
nonregen
anaemia
show
myelofibrosi
theileriasp
detect
four
dog
theileria
equi
two
dog
imidocarb
dipropion
administ
dog
treatment
choic
theileriosi
five
dog
receiv
complet
treatment
achiev
clinic
cure
pcr
posttreat
perform
three
dog
neg
prednisolon
azathioprin
administ
dog
suspect
immunemedi
haematolog
disord
secondari
theileriosi
one
dog
euthanas
one
week
diagnosiscanin
theileriosi
consid
differenti
diagnosi
dog
thrombocytopaenia
andor
anaemia
endem
tickborn
diseas
area
pcr
versatil
tool
diagnosi
treatment
monitor
theileriosi
studi
imidocarb
dipropion
effect
steril
parasit
infect
bleed
tendenc
seen
theileriosi
case
like
secondari
thrombocytopaenia
andor
concurr
thrombocytopathi
describ
canin
ehrlichiosi
studi
requir
determin
possibl
link
thrombocytopaenia
anaemia
myeloprolif
disord
observ
canin
theileriosi
al
proksch
unter
u
truyen
rs
mueller
k
hartmann
clinic
small
anim
medicin
lmu
univers
munich
munich
germani
institut
anim
hygien
veterinari
public
health
univers
leipzig
leipzig
germani
canin
parvovirosi
still
common
sever
diseas
especi
puppi
need
drug
decreas
sever
symptom
acceler
recoveri
paramun
induc
pindorf
stimul
immun
system
therefor
aim
studi
investig
whether
pindorf
use
addit
drug
lead
faster
recoveri
dog
parvovirosisin
total
dog
parvovirosi
randomli
assign
two
group
dog
dog
infect
canin
parvoviru
diagnos
fecal
elisa
polymeras
chain
reaction
pcr
also
dog
clinic
sign
studi
perform
prospect
placebocontrol
doubleblind
trial
dog
receiv
either
pindorf
placebo
addit
standard
treatment
canin
parvovirosi
clinic
score
complet
blood
count
serum
protein
albumin
evalu
daili
day
day
viral
shed
measur
day
fecal
pcr
viru
isolationno
signific
differ
could
found
clinic
score
blood
paramet
durat
viru
shed
compar
dog
receiv
pindorf
dog
receiv
placebo
signific
differ
increas
lymphocyt
count
observ
pindorf
group
three
dog
receiv
placebo
surviv
signific
differ
group
determin
concern
surviv
ratein
studi
signific
influenc
paramun
induc
pindorf
cours
parvovirosi
determin
therefor
indic
recommend
pindorf
therapi
canin
parvovirosi
microscop
agglutin
test
mat
current
consid
gold
standard
diagnosi
leptospirosi
dog
howev
perfect
tool
predict
infect
serogroup
crossreact
paradox
reaction
exist
object
studi
determin
infect
serovar
dog
posit
polymeras
chain
reaction
pcr
one
biolog
sampl
molecular
type
compar
result
provid
highest
mat
titer
dogfortyon
posit
pcr
biolog
sampl
urin
sampl
blood
sampl
one
kidney
sampl
one
cerebrospin
fluid
csfsampl
dog
clinic
suspicion
leptospirosi
least
one
posit
pcr
blood
urin
kidney
csf
kit
taqvet
pathogen
leptospira
lsi
franc
submit
molecular
type
genomospeci
first
determin
partial
rpob
partial
rrna
gene
sequenc
serovar
identifi
multipl
loci
variabl
number
tandem
repeat
analysi
mlva
three
variabl
number
tandem
repeat
vntr
loci
use
marker
serovar
identificationth
genomospeci
leptospira
interrogan
sensu
stricto
sampl
belong
dog
leptospira
borgpetersenii
three
sampl
three
dog
leptospira
kirschneri
two
sampl
two
dog
interestingli
one
dog
found
differ
speci
blood
urin
mlva
could
unequivoc
determin
infect
serovar
sampl
belong
dog
australi
one
dog
muenchen
three
dog
fugi
one
dog
canicola
two
dog
autumnali
six
dog
two
dog
among
infect
serovar
identifi
mlva
belong
infect
serogroup
identifi
mat
sampl
belong
dog
mlva
fail
identifi
infect
serovar
one
marker
could
amplifi
sampl
belong
dog
amplif
profil
suggest
coinfect
infect
serovar
previous
character
mlva
must
note
dog
abl
character
serovar
singl
kind
sampledespit
lack
sensit
mlva
appli
clinic
strain
studi
rapid
method
could
contribut
better
knowledg
epidemiolog
canin
leptospirosi
adapt
choic
marker
recent
two
trichomonad
identifi
diarrheal
stool
puppi
pentatrichomonashomini
ph
tritrichomona
foetu
tf
tf
infect
cat
result
chronic
coliti
howev
dog
pathogen
tf
ph
never
studi
object
studi
evalu
associ
trichomonad
infect
puppi
presenc
diarrheafaec
sampl
collect
prospect
puppi
week
age
french
breed
kennel
puppi
rectal
swab
perform
fecal
consist
evalu
use
numer
scale
liquid
fece
hard
fece
detect
trichomonad
perform
use
commerci
avail
system
pouchtm
tf
test
biom
diagnost
oregon
usa
evalu
media
done
alreadi
describ
observ
motil
trichomonad
organ
system
cultur
consid
posit
result
nine
posit
cultur
system
one
kennel
frozen
singletub
nest
pcr
assay
perform
order
sequenc
identifi
cultur
posit
puppi
gastrointestin
troubl
puppi
infect
trichomonad
significantli
digest
problem
puppi
infect
vs
p
ph
systemat
isol
posit
culturesph
trichomonad
isol
nine
cultur
system
test
singletub
nest
pcr
assay
result
show
poor
specif
medium
distinguish
tf
ph
observ
underlin
necess
use
pcr
precis
identif
type
trichomonad
trichomonad
significantli
associ
presenc
digest
disord
puppi
etiolog
studi
subject
consid
coinfect
fli
snap
flybit
jaw
snap
name
given
syndrom
dog
appear
watch
someth
suddenli
leap
snap
flybit
dog
gener
refer
neurologist
behaviourist
abnorm
often
interpret
focal
seizur
obsess
compuls
disord
ocd
one
publish
case
report
fli
bite
presum
caus
dietari
intoler
cavali
king
charl
spanielth
aim
case
seri
character
fli
bite
perform
complet
medic
evalu
dog
present
fli
bite
evalu
outcom
behaviour
follow
appropri
treatment
underli
medic
conditionseven
dog
present
flybit
behaviour
fb
assess
dog
underw
complet
medic
behaviour
histori
well
physic
neurolog
examin
investig
perform
abnorm
found
examin
histori
suggest
underli
problem
base
clinic
present
physic
examin
neurolog
examin
laboratori
test
result
diagnosi
made
specif
treatment
recommend
respons
treatment
monitor
evalu
follow
phone
convers
owner
day
onset
treatment
mani
gastrointestin
disord
found
fb
dog
includ
eosinophil
lymphoplasmacyt
infiltr
stomach
small
bowel
delay
gastric
empti
gastroeosophag
reflux
complet
resolut
fb
observ
dog
diagnos
specif
treat
underli
gastrointestin
gi
diseas
one
dog
diagnos
chiari
malform
respond
temporarili
pain
managementin
conclus
prospect
case
seri
indic
fli
bite
behaviour
may
caus
underli
medic
disord
gi
diseas
common
resolut
behaviour
possibl
follow
specif
treatment
underli
medic
condit
although
sever
diagnost
test
develop
diagnos
fip
still
difficulti
differenti
fip
diseas
similar
clinic
appear
vivo
fip
inflammatori
diseas
therefor
inflammatori
condit
concentr
app
expect
increas
aim
studi
evalu
abil
app
distinguish
fip
diseasesserum
sampl
cat
present
effus
obtain
measur
three
app
diagnost
workup
perform
respect
fip
jvim
diagnost
procedur
perform
depend
medic
condit
cat
diagnos
fip
cat
anoth
diseas
cardiac
tumor
serum
amyloid
saa
haptoglobin
hp
measur
autom
analys
use
felin
valid
assay
eiken
tridelta
respect
glycoprotein
agp
measur
use
manual
method
base
singl
radial
immunodiffus
tridelta
median
concentr
saa
hp
agp
significantli
p
higher
cat
fip
compar
cat
without
fip
saa
rang
lgml
rang
lgml
hp
rang
mgml
rang
mgml
agp
rang
lgml
rang
lgml
major
felin
app
seem
use
diagnost
tool
help
differenti
fip
diseas
howev
concentr
app
diseas
septic
process
dissemin
neoplasia
high
fip
protothecosi
uncommon
diseas
peopl
anim
caus
prototheca
spp
unicellular
aerob
alga
date
case
describ
dog
north
america
australia
europ
case
document
last
decad
poland
itali
greec
spain
affect
dog
show
sign
refer
gastrointestin
tract
particularli
colon
ocular
neurolog
sign
also
report
diseas
insidi
onset
slow
progress
fatal
cours
aim
present
studi
describ
clinic
laboratori
find
case
canin
protothecosi
north
itali
diagnos
medic
record
retriev
inform
pertain
histori
clinic
instrument
data
well
followup
collectedth
median
age
dog
year
rang
femal
boxer
major
complaint
chronic
larg
bowel
diarrhea
hematochezia
weight
loss
observ
sinc
median
time
month
rang
previou
treatment
gastrointestin
diet
antiparasit
drug
antibiot
yield
improv
addit
dog
develop
uveiti
diseas
cours
dog
complet
blood
count
serum
biochem
profil
includ
protein
electrophoresi
abdomin
ultrasound
perform
serum
ctli
folat
cobalamin
avail
dog
urinalysi
one
result
laboratori
test
normal
ultrasonographi
unremark
dog
show
increas
colon
wall
thick
definit
diagnosi
obtain
endoscop
biopsi
colon
andor
rectal
scrape
dog
biopsi
colon
necropsi
one
case
spheroid
ovoid
irregularlyshap
organ
suggest
prototheca
spp
observ
differ
treatment
attempt
without
benefit
dog
one
dog
transient
improv
obtain
itraconazol
median
surviv
time
month
rang
present
work
indic
protothecosi
includ
list
differenti
diagnosi
dog
larg
bowel
diarrhea
especi
chronic
refractori
coliti
develop
ocular
sign
dog
infect
prototheca
spp
guard
prognosi
diagnos
protothecosi
dog
period
may
suggest
diseas
emerg
southern
european
countri
idiopath
pulmonari
fibrosi
ipf
interstiti
fibrot
pulmonari
diseas
mainli
describ
west
highland
white
terrier
whwt
diagnosi
challeng
ultim
reli
lung
histopatholog
identif
biomark
specif
diseas
would
help
chemotact
cytokin
monocyt
known
biomark
human
ipf
dog
ipf
increas
gene
express
describ
lung
tissu
aim
present
studi
compar
serum
concentr
dog
ipf
versu
healthi
dog
dog
chronic
pulmonari
diseasesthirteen
dog
ipf
ten
whwt
two
scottish
terrier
one
yorkshir
mean
age
year
rang
nine
dog
eosinophil
bronchopneumopathi
ebp
variou
breed
year
ten
dog
chronic
bronchiti
cb
variou
breed
year
ten
healthi
whwt
year
enter
studi
diagnosi
establish
clinic
radiograph
bronchoscop
balf
analysi
examin
well
dog
ipf
either
lung
high
resolut
comput
tomographi
six
dog
histopatholog
three
dog
four
dog
concentr
serum
determin
elisa
canin
r
sytem
result
differ
group
compar
use
nonparametr
test
mannwhitney
rank
sum
test
serum
concentr
elev
dog
ipf
median
interquartil
rang
pgml
compar
healthi
whwt
p
serum
valu
ipf
dog
higher
ebp
dog
cb
dog
present
studi
show
idiopath
pulmonari
fibrosi
ipf
progress
interstiti
fibrot
diseas
describ
human
dog
etiolog
pathogenesi
ipf
poorli
known
speci
even
genet
basi
suspect
dog
predisposit
west
highland
white
terrier
whwt
serum
transform
growth
factor
beta
concentr
elev
healthi
whwt
whwt
ipf
compar
healthi
dog
variou
breed
human
ipf
pathway
involv
cytokin
profibrot
properti
seem
central
pathogenesi
consid
potenti
therapeut
target
produc
proprotein
usual
store
latent
complex
activ
latent
complex
import
step
regul
function
multipl
activ
mechan
identifi
includ
bind
integrin
thrombospondin
aim
present
studi
quantifi
express
well
express
protein
involv
activ
quantit
rtpcr
lung
tissu
dog
ipf
versu
control
dogstot
rna
extract
lung
tissu
dog
ipf
whwt
scottish
terrier
lhassa
apso
control
dog
variou
breed
ipf
confirm
histopatholog
sampl
express
integrin
measur
qrtpcr
gene
rel
copi
number
calcul
sampl
result
normalis
use
two
stabli
express
housekeep
gene
tbp
statist
signific
differ
group
assess
use
student
ttest
mannwhitney
rank
sum
test
signific
defin
p
statist
differ
two
group
express
significantli
lower
p
express
significantli
higher
ipf
group
rel
controlsresult
present
studi
could
confirm
increas
gene
express
lung
tissu
sourc
high
circul
level
ipf
studi
highlight
differ
activ
pathway
ipf
lung
compar
control
lung
shift
toward
increas
activ
via
canin
ipf
obes
common
nutrit
problem
dog
detriment
effect
basal
lung
function
paramet
recent
shown
use
wholebodi
barometr
plethysmographi
walk
test
recent
demonstr
noninvas
easytoperform
test
clinic
set
abl
discrimin
healthi
dog
dog
pulmonari
diseaseth
aim
studi
investig
effect
bodi
weight
loss
bwl
pulmonari
function
assess
arteri
blood
ga
valuessix
experiment
beagl
privatelyown
dog
obes
otherwis
healthi
enrol
dietinduc
bwl
program
physic
examin
bw
bodi
condit
score
bc
assess
arteri
blood
ga
analysi
perform
dog
obes
bc
repeat
anim
middl
bwl
program
overweight
bc
end
lean
bc
dog
walk
minut
along
insid
hallway
heart
rate
hr
oxygen
satur
measur
puls
oximetri
test
pretest
valu
three
minut
walk
midtest
valu
minut
posttestal
dog
conclud
bwl
program
initi
bw
kg
final
bw
p
bwl
caus
signific
increas
walk
distanc
lean
overweight
obes
p
decreas
pretest
respiratori
rate
rr
lean
overweight
min
obes
p
rest
arteri
blood
ga
result
influenc
bwl
neither
pretest
hr
valu
measur
puls
oximetri
obes
dog
show
signific
higher
hr
midtest
valu
compar
overweight
lean
dog
lean
overweight
obes
p
moreov
valu
record
minut
posttest
significantli
higher
overweight
lean
dog
compar
obes
dog
also
hr
valu
regist
minut
posttest
lower
overweight
lean
dogsin
conclus
obes
neg
affect
blood
oxygen
level
shortli
physic
exercis
dog
subsequ
hr
increas
bwl
induc
signific
decreas
rest
rr
improv
pulmonari
function
exercis
even
achiev
target
ideal
bw
pretest
arteri
blood
ga
valu
effici
tool
demonstr
efficaci
bwl
diagnost
laboratori
method
avail
evalu
platelet
function
contribut
thrombot
event
clinic
set
imped
whole
blood
platelet
aggregomet
multipl
recent
becom
avail
although
market
monitor
effect
antiplatelet
therapi
also
use
assess
platelet
aggreg
respons
variou
agonist
reflect
platelet
function
activ
reactiv
respons
diseas
purpos
studi
therefor
investig
multipl
diagnost
tool
detect
variat
platelet
aggreg
dog
diseas
known
predispos
hypercoagul
thrombosi
evalu
whether
correl
multipl
aggreg
respons
maxim
amplitud
measur
thromboelastographi
teg
twenti
clinic
healthi
dog
eighteen
diseas
dog
neoplasia
gener
inflamm
protein
lose
enteropathi
ornephropathi
admit
univers
hospit
companion
anim
univers
copenhagen
includ
studi
citrat
heparinis
blood
sampl
collect
multipl
aggreg
perform
dilut
heparinis
whole
blood
minut
use
adp
collagen
col
arachidon
acid
aa
agonist
nacl
buffer
control
result
record
area
curv
auc
dilut
tissu
factor
teg
analys
perform
citrat
whole
blooddiseas
dog
significantli
increas
auc
compar
healthi
dog
nacl
buffer
control
adp
p
col
wherea
signific
differ
obtain
aa
agonist
tegma
significantli
higher
diseas
dog
compar
healthi
dog
signific
correl
found
tegma
multipl
auc
use
adp
col
aa
result
demonstr
multipl
aggreg
respons
significantli
increas
popul
diseas
dog
diseas
known
predispos
hypercoagul
thrombosi
result
significantli
correl
tegma
suggest
multipl
method
use
detect
increas
platelet
reactiv
dog
diseas
known
predispos
hypercoagul
thrombosi
multipl
provid
addit
inform
platelet
function
teg
alon
patient
group
studi
need
determin
multipl
tegma
result
correl
thrombosi
whether
may
ad
benefit
use
combin
hypoalbuminaemia
commonli
identifi
biochem
dyscrasia
clinic
impact
far
reach
particularli
sever
affect
anim
problem
recognis
ensu
includ
alter
colloid
osmot
pressur
caviti
effus
clot
abnorm
alter
carriag
drug
hormon
electrolyt
along
acidbas
disturbancesth
aim
studi
determin
incid
side
effect
encount
administ
intraven
human
albumin
dog
suffer
hypoalbuminaemia
anim
present
specialist
referr
centr
hampshir
uk
variou
condit
result
hypoalbuminaemia
hypoalbuminaeamia
consid
present
serum
albumin
concentr
total
albumin
infus
given
dog
present
serum
albumin
concentr
lower
albumin
given
intraven
infus
kg
follow
premed
chlorphenamin
durat
administr
minut
hour
dog
monitor
potenti
advers
reaction
administr
albumin
postinfus
period
potenti
advers
reaction
includ
hypotens
hyperthermia
tachycardia
tachypnea
peripher
oedema
agitationrestless
collaps
none
anim
show
advers
reaction
administr
albumin
postinfus
period
one
anim
demonstr
mild
hyperaesthesia
resolv
prior
complet
infusionof
anim
present
surviv
discharg
anim
euthanas
die
dog
receiv
averag
sd
albumin
infus
period
hospitalis
signific
differ
start
albumin
concentr
survivor
nonsurvivor
signific
differ
increas
albumin
concentr
postinfus
survivor
nonsurvivor
signific
differ
number
albumin
infus
survivor
nonsurvivor
concentr
albumin
preinfus
neg
impact
surviv
discharg
hospit
result
studi
demonstr
signific
complic
follow
administr
human
albumin
solut
dog
associ
administr
albumin
number
albumin
infus
amount
albumin
administ
patient
outcom
albumin
infus
may
improv
chanc
sever
hypoalbuminaem
dog
surviv
discharg
hospit
use
human
albumin
purpos
enabl
limit
suppli
canin
plasma
reserv
dog
need
plasma
transfus
reason
recent
metabol
syndrom
gain
attent
human
medicin
given
associ
develop
diabet
mellitu
cardiovascular
diseas
canin
obes
associ
develop
insulin
resist
alter
lipid
profil
mild
hypertens
author
awar
exist
studi
examin
exist
ms
obes
dog
thirtyf
obes
dog
assess
weight
loss
guidelin
intern
diabet
feder
modifi
order
produc
definit
canin
metabol
syndrom
cm
includ
measur
adipos
use
bodi
condit
score
bc
systol
blood
pressur
plasma
cholesterol
plasma
triglycerid
plasma
glucos
urin
protein
creatinin
ratio
upcr
way
comparison
total
region
bodi
fat
mass
assess
dualenergi
xray
absorptiometri
whilst
adiponectin
insulin
highsensit
creactiv
protein
hscrp
also
assess
valid
assayssystol
blood
pressur
cholesterol
triglycerid
insulin
p
upcr
decreas
weight
loss
whilst
plasma
adiponectin
increas
howev
hscrp
chang
weight
loss
prior
weight
loss
dog
defin
cm
differ
total
region
bodi
fat
mass
dog
fit
definit
cm
howev
plasma
adiponectin
concentr
less
plasma
insulin
concentr
greater
cm
dogsin
studi
third
obes
dog
suffer
cm
character
hypoadiponectinaemia
hyperinsulinaemia
studi
form
basi
investig
determin
pathogenet
mechan
health
signific
dog
term
diseas
associ
outcom
weight
loss
cystourethroscopi
greatli
enhanc
diagnosi
treatment
numer
condit
veterinari
medicin
rigid
telescop
use
femal
cytoscopi
provid
wellillumin
highli
detail
imag
use
rod
len
system
technolog
flexibl
ureteroscop
use
male
urethrocytoscopi
limit
imag
qualiti
procedur
abil
due
fiberopt
system
diminish
illumin
smaller
work
channel
purpos
studi
describ
techniqu
efficaci
complic
use
novel
percutan
perin
approach
male
urethra
order
gain
access
rigid
cystoscopyth
perin
approach
perform
ten
time
nine
dog
ectop
uret
laser
ablat
idiopath
renal
hematuria
sclerotherapi
dog
place
dorsal
recumb
use
fluoroscop
guidanc
gaug
renal
access
needl
advanc
transperin
pelvic
urethra
guidewir
access
obtain
access
site
dilat
accept
peelaway
sheath
rigid
cystoscop
place
sheath
perform
procedur
urinari
cathet
place
follow
three
ten
procedur
three
eighteen
hour
identifi
periop
minor
complic
includ
urin
form
perin
site
approxim
six
hour
postop
singl
dog
sign
stranguria
pollakiuria
incision
complic
identifi
dog
postop
followup
examin
contact
rang
day
percutan
perin
approach
male
dog
rigid
cystoscopi
appear
safe
effect
mean
facilit
endoscop
procedur
irh
result
chronic
upper
urinari
tract
bleed
human
ruptur
renal
pelvic
hemangiomasangioma
typic
caus
although
benign
anemia
ureter
urethr
obstruct
ensu
advent
endourolog
renalspar
therapi
like
ureteropyeloscopicguid
electrocauteri
sclerotherapi
replac
ureteronephrectomi
object
describ
use
endoscopicfluoroscopicguid
sclerotherapi
treatment
irh
dog
report
first
clinic
outcomeseach
uvj
identifi
cystoscop
bleed
confirm
retrograd
ureteropyelogram
perform
ureteropelv
junction
balloon
use
ureter
occlus
pelvi
fill
volum
record
four
dwell
perform
povidon
iodin
mixtur
steril
liquid
silver
nitrat
doublepigtail
ureter
stent
placedseven
dog
sclerotherapi
five
unilater
bilater
develop
contralater
bleed
unit
five
right
leftsid
male
femal
median
age
weight
year
respect
median
procedur
time
minut
complic
sever
renal
discomfort
pyelectasia
unstent
dogcess
hematuria
occur
renal
unit
median
hour
two
recurr
within
week
resort
intermitt
mild
hematuria
two
fail
treatment
median
followup
time
month
rang
overal
topic
sclerotherapi
irh
safe
effect
first
report
local
sclerotherapi
irh
dog
could
consid
valuabl
endoscopicguid
therapi
prior
ureteronephrectomi
investig
requir
percutan
nephrolithotomi
pcnl
consid
standard
ofcar
remov
nephrolith
cm
peopl
minim
morbid
preserv
renal
function
success
rate
report
veterinari
nephrolith
remain
clinic
silent
remov
recommend
complic
stone
morbid
nephrotomi
sever
object
describ
endoscopicguid
nephrolithotomi
enl
canin
felin
patient
report
clinic
outcom
hypothes
safe
effect
patient
either
pcnl
surgicallyassist
endoscop
nephrolithotomi
senl
retrospect
evalu
renal
punctur
needl
balloondilationsheath
combin
use
tract
format
nephroscop
provid
visual
intracorpor
lithotripsi
stone
fragment
remov
ureter
stent
place
nine
dog
cat
renal
unit
includ
four
pcnl
senl
indic
includ
recurr
uti
worsen
azotemia
ureteraloutflow
obstruct
median
weight
kg
stone
composit
calcium
oxal
mix
struvit
urat
cystin
median
stone
size
cm
median
preand
month
postop
creatinin
mgdl
respect
median
procedur
time
minut
success
remov
stone
document
procedurerel
complic
occur
unit
easili
manag
median
followup
time
day
four
patient
still
aliv
patient
die
procedur
overal
enl
safe
perform
dog
cat
yield
similar
success
rate
peopl
advanc
endourolog
experi
recommend
key
regul
plasma
phosphat
concentr
elev
cat
natur
occur
ckd
increas
renal
function
declin
elev
concentr
independ
predictor
surviv
time
human
haemodialysi
patient
associ
previous
examin
cat
ckd
studi
investig
independ
associ
surviv
time
caus
mortal
cat
newli
diagnos
ckdcat
diagnos
ckd
two
londonbas
first
opinion
practic
identifi
ckd
defin
plasma
creatinin
concentr
concurr
urin
specif
graviti
usg
plasma
creatinin
concentr
two
consecut
visit
cat
exclud
residu
edta
plasma
avail
measur
plasma
concentr
within
day
date
diagnosi
ckd
concentr
measur
use
previous
valid
human
intact
elisa
plasma
creatinin
phosphat
total
calcium
concentr
pack
cell
volum
pcv
systol
blood
pressur
sbp
usg
age
enter
univari
cox
regress
model
surviv
time
concentr
logarithm
transform
due
highli
skew
distribut
statist
signific
defin
p
variabl
p
carri
forward
backward
stepwis
multivari
cox
regress
analysi
surviv
time
ninetyon
cat
includ
studi
end
followup
period
februari
cat
euthanas
die
median
rang
surviv
time
day
cat
aliv
lost
followup
median
rang
surviv
time
day
median
rang
age
diagnosi
year
univari
cox
regress
analysi
indic
plasma
creatinin
p
phosphat
p
p
concentr
neg
associ
surviv
time
pcv
p
usg
p
posit
associ
surviv
time
multivari
model
plasma
hazard
ratio
hr
confid
interv
ci
creatinin
concentr
ci
p
neg
associ
surviv
time
pcv
ci
posit
associ
surviv
timeplasma
concentr
novel
prognost
indic
felin
ckd
independ
factor
includ
plasma
creatinin
concentr
pcv
futur
studi
investig
whether
